DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
i  
 
A Phase IV Double -Blind,  Placebo -Controlled,  Randomized Trial  to Evaluate  
Short  Course  vs. Standard Course  Outpatient  Therapy  of 
Community  Acquired Pneumonia  in Children (SCOUT -CAP)  
 
  
DMID  PROTOCOL  NUMBER:  14-0079  
 
DMID  FUNDING  MECHANISM:   VACCINE AND TREATMENT EVALUATION UNIT  
IND SPONSOR:  NIH/NIAID/ DMID  
VTEU  PRINCIPAL  INVESTIGATOR:  C. BUDDY  CREECH,  MD, MPH  
ARLG  PRINCIPAL  INVESTIGATOR S:  W. CHARLES  HUSKINS,  MD, MSC  
& THEOKLIS  ZAOUKIS,  MD, MCSE  
 
 
VERSION  NUMBER:  4.0 
14 DEC EMBER 2018  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
ii STATEMENT  OF COMPLIANCE  
 
This trial will be carried out in accordance  with Good  Clinical Practices  (GCP)  as required  by the 
following: 
• United  States  Code  of Federal  Regulations  (CFR)  applicable to clinical studies  (45 CFR 
Part 46; 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312);  
• International  Conference  on Harmonization (ICH)  E6; 62 Federal  Register  25691 (1997);  
• The Health  Insurance Portability  and Accountability  Act (HIPAA)  Privacy Rule-Final  
Modification  (45 CFR Parts  160 and 164);  
• National  Institutes  of Health  (NIH)  Clinical Terms  of Award,  as applicable.  
Compliance with these standards  provides  public  assurance  that the rights,  safety  and well-
being  of study  subjects  are protected,  consistent  with the principles  that have  their origin  in the 
Declaration of Helsinki. 
All key personnel  (all individuals  responsible for the design  and conduct  of this trial) have 
completed  Human  Subjects  Protection Training.  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
iii SIGNATURE  PAGE  
The signature  below  constitutes  the approval  of this protocol  and the attachments,  and provides  
the necessary  assurances  that this trial will be conducted according  to all stipulations  of the 
protocol,  including all statements  regarding  confidentiality,  and according to local legal  and 
regulatory  requirements  and applicable United  States  of America  (US) federal  regulations  and 
ICH guidelines.  
 
 
__________________________________________________________             
Site Principal  Investigator  Signature   
 
 
Date: _____________________ 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
iv TABLE  OF CONTENTS  
  Page  
Statement of Compliance ............................................................................................................ ii 
Signature Page  .......................................................................................................................... iii 
Table of Contents  ....................................................................................................................... iv 
List of Figures and Tables  ......................................................................................................... vii 
List of Abbreviations  ................................................................................................................. viii 
Protocol Summary  ..................................................................................................................... ix 
1 Key Roles  ......................................................................................................................... 11 
2 Background Information and Scientific Rationale.............................................................. 13 
2.1 Background Information  ........................................................................................ 13 
2.2 Rationale .............................................................................................................. 13 
2.3 Potential Risks and Benefits  ................................................................................. 14 
2.3.1  Potential Risks  .......................................................................................... 14 
2.3.2  Known Potential Benefits ........................................................................... 14 
3 Objectives  ........................................................................................................................ 15 
3.1 Study Objectives  ................................................................................................... 15 
3.2 Study Outcome Measures  .................................................................................... 15 
3.2.1  Primary Outcome Measures  ...................................................................... 15 
3.2.2  Secondary Outcome Measures  ................................................................. 17 
3.2.3  Exploratory Outcome Measures  ................................................................ 18 
4 Study Design  .................................................................................................................... 19 
5 Study Enrollment and Withdrawal  ..................................................................................... 21 
5.1 Subject Inclusion Criteria  ...................................................................................... 21 
5.2 Subject Exclusion Criteria ..................................................................................... 21 
5.3 Treatment Assignment Procedures  ....................................................................... 23 
5.3.1  Randomization Procedures  ....................................................................... 23 
5.3.2  Masking Procedures  .................................................................................. 23 
5.3.3  Reasons for Withdrawal ............................................................................ 24 
5.3.4  Handling of Withdrawals  ............................................................................ 25 
5.3.5  Termination of Study  ................................................................................. 25 
6 Study Intervention/Investigational Product ........................................................................ 26 
6.1 Study Product Description  .................................................................................... 26 
6.1.1  Acquisition  ................................................................................................. 26 
6.1.2  Formulation, Packaging, and Labeling....................................................... 26 
6.1.3  Product Storage and Stability  .................................................................... 28 
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  ................................................................................................................. 29 
6.2.1  Dosage  ...................................................................................................... 29 
6.2.2  Preparation  ................................................................. .. ............................ 29 
6.2.3  Administration  ........................................................................................... 29 
6.3 Modification of Study Intervention/Investigational Product for a Participant  ........... 29 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
v 6.4 Accountability Procedures for the Study Intervention/Investigational Product(s)  ... 30 
6.5 Assessment of Subject Compliance with Study Intervention/Inv estigational 
Product  ................................................................................................................. 30 
6.6 Concomitant Medications/Treatments  ...................................................................  30 
7 Study Schedule ................................................................................................................ 31 
7.1 Screening ............................................................................................................. 31 
7.2 Enrollment/Baseline  .............................................................................................. 31 
7.3 Follow -up .............................................................................................................. 33 
7.4 Final Study Visit  .................................................................................................... 34 
7.5 Early Termination Visit  .......................................................................................... 34 
8 Study Procedures/Evaluations  .......................................................................................... 36 
8.1 Clinical Evaluations  ............................................................................................... 36 
8.2 Laboratory Evaluations  ......................................................................................... 37 
8.2.1  Clinical Laboratory Evaluations  ................................................................. 37 
8.2.2  Special Assays or Procedures  ...................................................................  37 
8.2.3  Specimen Preparation, Handling, and Shipping ........................................ 37 
9 Assessment of Safety  ....................................................................................................... 39 
9.1 Specification of Safety Parameters  ....................................................................... 39 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ........................................................................................................... 40 
9.2.1  Adverse Events  ......................................................................................... 40 
9.2.2  Serious Adverse Events  ............................................................................ 40 
9.2.3  Procedures to be Followed in the Event of Abnormal Clinical Findings  ..... 42 
9.3 Reporting Procedures  ........................................................................................... 42 
9.3.1  Serious Adverse Events  ............................................................................ 42 
9.3.2  Regulatory Reporting for Studies Conducted Under DMID -Sponsored 
IND ............................................................................................................ 43 
9.4 Type and Duration of Follow -up of Subjects after Adverse Events  ........................ 43 
9.5 Halting Rules  ........................................................................................................ 43 
9.5.1  Study Halting Rules  ................................................................................... 43 
9.5.2  Individual Halting Rules (Termination of Study Product Administration) ..... 44 
9.6 Safety Oversight  ................................................................................................... 44 
9.6.1  Data  and Safety Monitoring Board (DSMB)  ............................................... 44 
10 Clinical Monitoring  ............................................................................................................ 46 
10.1  Site Monitoring Plan  ..............................................................................................  46 
11 Statistical Considerations  ................................................................................................. 47 
11.1  Study Hypothesis  .................................................................................................. 48 
11.2  Sample Size Considerations  ................................................................................. 48 
11.3  Planned Interim Analyses  ................................ ..................................................... 48 
11.3.
1 Safety Review  ........................................................................................... 48 
11.3.1  Interim Analysis of Efficacy, Futility, and Safety  ......................................... 49 
11.4  Final Analysis Plan ............................................................................................... 50 
11.4.1  Primary Analysis  ....................................................................................... 50 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
vi 11.4.2  Secondary Analyses  .................................................................................. 51 
11.4.3  Exploratory Analyses  ................................................................................. 52 
12 Source Documents and Access to Source Data/Documents  ............................................ 53 
13 Quality Control and Quality Assurance  ............................................................................. 54 
14 Ethics/Protection of Human Subjects  ................................................................................ 55 
14.1  Ethical Standard  ................................................................................................... 55 
14.2  Institutional Review Board .................................................................................... 55 
14.3  Informed Consent Process  ................................................................................... 55 
14.3.1  Informed Consent  ...................................................................................... 55 
14.3.2  Informed Consent/Assent Process (in Case of a Minor)  ............................ 56 
14.4  Exclusion of Women, Minorities, and Children (Special Populations)  .................... 56 
14.5  Subject Confidentiality  .......................................................................................... 56 
14.6  Future Use of Stored Specimens  .......................................................................... 57 
15 Data Handling and Record Keeping ................................................................................. 58 
15.1  Data Management Responsibilities  ....................................................................... 58 
15.2  Data Capture Methods  .......................................................................................... 58 
15.3  Types of Data  ....................................................................................................... 58 
15.4  Timing/Reports  ..................................................................................................... 59 
15.5  Study Records Retention  ...................................................................................... 59 
15.6  Protocol Deviations  ............................................................................................... 59 
16 Publication Policy  ............................................................................................................. 60 
17 Literature References  ....................................................................................................... 61 
APPENDIX A – Schedul e of Evaluations  ................................................................................... 62 
  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
vii LIST OF FIGURES AND TABLES  
 
 
Figure 1:Study Schematic  ........................................................................................................... x 
 
Table 1. Ordinal Outcome .........................................................................................................16 
Table 2: Severity of Cough  ........................................................................................................17 
Table 3. Solicited Events Grading .............................................................................................17 
  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
viii LIST OF ABBREVIATIONS  
AE Adverse  Event/Adverse  Experience  
ARLG  Antibiotic Resistance Leadership Group  
ATP According -to-Protocol  
CAP Community  Acquired  Pneumonia  
CC Complete Case  
CFR Code  of Federal  Regulations  
CMS  Clinical Materials Services  
DHHS  Department  of Health  and Human  Services  
DMID  Division  of Microbiology  and Infectious  Diseases,  NIAID,  NIH, DHHS  
DOOR  Desirability  of Outcome  Ranking  
DSMB  Data  and Safety  Monitoring  Board  
eCRF  Electronic  Case  Report  Form  
ED Emergency Department  
EHR  Electronic Health Record  
FDA Food  and Drug  Administration  
FWA  Federalwide  Assurance  
GCP  Good  Clinical  Practice  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
ICH International  Conference  on Harmonisation  
ICMJE  International  Committee of Medical  Journal  Editors  
IDES Internet Data Entry System  
IDSA  Infectious  Diseases  Society  of America  
IEC Independent  or Institutional  Ethics  Committee  
IND Investigational  New Drug  Application  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
ITT Intention -to-Treat  
MOP  Manual  of Procedures  
NIAID  National  Institute  of Allergy  and Infectious  Diseases,  NIH, DHHS  
NIH National  Institutes  of Health  
OHRP  Office  for Human  Research  Protections  
PI Principal  Investigator  
QA Quality  Assurance  
QC Quality  Control  
RADAR  Response Adjusted for Days of Antibiotic Risk  
SAE Serious  Adverse  Event/Serious  Adverse  Experience  
SDCC  Statistical and Data Coordinating Center  
  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
US United  States  
USP United States Pharmacopeia  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
ix PROTOCOL SUMMARY  
Title:  A Phase IV Double- Blind,  Placebo- Controlled,  Randomized Trial 
to Evaluate Short  Course  vs. Standard Course  Outpatient  
Therapy  of Community  Acquired  Pneumonia  in Children 
(SCOUT -CAP)  
Phase:  IV 
Population:  Approximately 400 subjects  aged 6- 71 months  of age with 
community  acqu ired pneumonia  (CAP)  
Description of 
Sites/Facilities Enrolling 
Participants:  5 to 10 US outpatient sites  
Study  Duration:  25 months  
Subject  Participation  
Duration:  ~1 month  after beginning antibiotic  therapy  
Description of Agent  or 
Intervention:  Oral suspensions of amoxicillin,  amoxicillin -clavulanate,  cefdinir  
and matching  placebos  
Objectives: 
  
Primary:  
1. To compare the composite overall  outcome (Desirability  
of Outcome  Ranking,  DOOR)  among  children 6- 71 
months of age  with CAP assigned  to a strategy  of short  
course (5 days)  vs. standard course (10 days)  outpatient  
beta- lactam  therapy  at Outcome  Assessment Visit #1 
(Study Day 8 +/- 2 days ) 
 
Secondary:  
1. To compare the composite overall  outcome (DOOR)  
among  children  6-71 months  of age with CAP assigned 
to a strategy  of short  course (5 days)  vs standard course 
(10 days)  outpatient  beta- lactam  therapy  at Outcome  
Assessment Visit #2 (Study Day 22 +/ - 3 days ) 
2. To compare the resolution of symptoms (a component of 
DOOR) among  children  6-71 months  of age with CAP 
assigned  to a strategy  of short  course (5 days)  vs 
standard  course (10 days)  outpatient  beta-lactam  
therapy  at Outcome Assessment Visits #1 and #2  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
x 3. To compare the clinical response (a component  of 
DOOR)  among  children  6-71 months  of age with CAP 
assigned  to a strategy  of short  course (5 days)  vs 
standard  course (10 days)  outpatient  beta-lactam  
therapy  at Outcome  Assessment  Visits #1 and #2  
4. To compare solicited  events  (a component  of DOOR)  
among  children  6-71 months  of age with CAP assigned 
to a strategy  of short  course (5 days)  vs standard course 
(10 days)  outpatient  beta- lactam  therapy  at Outcome  
Assessment Visits  #1 and #2  
5. To compare medically  attended visits  to Emergency  
Departments  (ED) or outpatient  clinic s, hospitalizations , 
surgical  procedures , and receipt  of non-study  systemic 
antibiotic s (components  of the clinical response)  among  
children 6- 71 months of age with CAP assigned  to a 
strategy  of short  course (5 days)  vs standard  course (10 
days)  outpatient  beta-lactam  therapy  at Outcome  
Assessment Visits  #1 and #2  
 
Exploratory : 
1. To examine the robustness of results of DOOR 
comparisons when increasing the threshold in assigning 
different ranks due to differing numbers of days of 
antibiotic use from a one day difference to a two, three, 
four, or five day  difference.  
 
Description of Study  
Design:  Double- Blind,  Placebo- Controlled,  Randomized Trial 
Estimated Time to 
Complete  Enrollment:  Approximately 24 months  
 
 
Figure 1:Study Schematic  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
11 1 KEY ROLES  
Individuals:  Principal Investigator  
 C. Buddy  Creech,  MD, MPH  
Associate Professor  of Pediatrics,  Division  of Pediatric  Infectious  
Diseases  
Director,  Vanderbilt  Vaccine Research Program  
CCC- 5319 Medical  Center  North  
1161 21st Avenue South  
Nashville,  TN 37232  
Phone: 615- 343-0332  
Email:  buddy.creech@vanderbilt.edu  
 
 Antibiotic Resistance Leadership Group (ARLG)  Protocol 
Co-Principal Investigators 
W. Charles  Huskins,  MD, MSc  
Mayo  Clinic   
200 First Street  SW  
Rochester, MN 55905 
Phone: 507-255-8464   
Email:  huskins.charles@mayo.edu 
 
 Theoklis  Zaoutis,  MD, MSCE  
The Children's  Hospital  of Philadelphia,   
34th and Civic  Center  Boulevard,   
CHOP  North,  Room  1527,   
Philadelphia,  PA 19104  
Phone: (267)  426-5570  
Email:  zaoutis@email.chop.edu  
 National Institutes of Health  
DMID Medical Monitor  
Venus Shahamatdar, MD 
DMID/NIAID/NIH/HHS  
5601 Fishers Lane, 7E54 
Rockville, MD 20852  
Phone: (240) 627- 3369  
Email: shahamav@mail.nih.gov  
 
 
Statistical and Data Coordinating Center :  
The Emmes Corporation  
401 N. Washington St. Suite 700  
Rockville, MD  20850 
Phone: 301- 251-1161  
Email: arlg_studies@emmes.com   
  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
12 Safety and  
Pharmacovigilance 
Contractor:  
 DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20814 SAE Hot Line: 1- 800-537-9979 (US)  
SAE Fax: 800- 275-7619 (US)  
SAE Email: PVG@dmidcroms.com  
  
Clinical  Materials 
Services Fisher BioServices  
c/o DMID Clinical Materials Services  
20439 Seneca Meadows Parkway  
Germantown, MD 20876 Phone: 240- 477-1350  
Fax: 240- 477-1360  
Email: DMID.CMS@ThermoFisher.com  
  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
13 2 BACKGROUND  INFORMATION AND  SCIENTIFIC 
RATIONALE  
2.1 Background Information  
The World Health  Organization estimates  156 million  cases  of pneumonia occur  annually  in 
children <5 years  of age.1 In the United  States  (US), an estimated  1.5 million  ambulatory  visits  
for community -acquired  pneumonia (CAP) in children occur annually.2 Hospitalizations  for CAP 
in children have decreased after the introduction of pneumococcal  conjugate vaccine.3 Further, 
in a pneumonia etiology study of >2500 children hospitalized with CAP in 3 US cities  between 
2010 and 2012, viral pathogens accounted for >70% of detections, while bacteria were 
identified in <20% .4 However,  ambulatory  visits  have  not decreased, and pediatric CAP remains  
a very common  infection  for which  antibi otics are generally  prescribed.2 
 
A 2011 Infectious  Diseases  Society  of America  (IDSA)  guideline for management  of CAP in 
children provides  recommendations  for antibiotic  therapy.5 Regarding  the treatment  duration for 
beta- lactam  antibiotics,  the guideline states  “courses  of 10 days  have been best studied.”  Two 
studies  conducted  in resource- poor settings  found no difference in outcomes  between 3 vs. 5 
days  of oral therapy  or 3 days  of oral therapy  vs. placebo for non-severe pneumonia.6,7 
However,  these  studies  likely  included many  subjects with viral infection  because substantial  
proportions  had no radiographic  findings  or included children with wheezing.  While s tating  
“shorter  courses  may be just as effective,”  the IDSA  guideline concluded there  was insufficient 
evidence to recomm end short  course therapy.5 The guideline identified  clinical trials  that provide 
information  on the “shortest  duration of therapy  to decrease  the development  of antimicrobial  
resistance  and the risk of antimicrobial  toxicity”  as a priority  for future  research.5 
 
2.2 Rationale  
 
In 2014,  a randomized trial of short  vs. standard course therapy  in young children in Israel  with 
CAP suspected  to be of bacterial  origin  found a higher  rate of treatment  failure  (40%)  in subjects  
treated for only 3 days  vs. subjects  treated  for 5 or 10 days.8 The study  was underpowered to 
detect  a difference in treatment  failure  between subjects  treated for 5 vs. 10 days,  but treatment  
failure  did not occur in either  group.   
 The proposed  study  will test the effectiveness  of short  (5-day) vs. standard  (10-day) course 
therapy  in children who are diagnosed with CAP and initially  treated in outpatient  clinics , urgent  
care facilities,  and emergency  departments.  The study will specifically address whether short 
course therapy is superior to standard therapy among children that have clinically improved 
since diagnosis. If superior  to standard  course therapy,  short  course  therapy  could reduce 
antibiotic  exposure among  young  children.  We will use a study  methodology  similar  to the 
SCOUT  Study  (“Short  Cour
 se Therapy  for Urinary  Tract  Infections  in Children”) —a randomized,  
double- blind,  placebo- controlled non-inferiority  trial of short  course antimicrobial  therapy  for 
urinary  tract infection  in children sponsored  by NIAID  through  the “Targeted  Clinical Trials  to 
Reduce the Risk of Antimicrobial  Resistance”  initiative.   However,  the SCOUT -CAP trial will use 
a superiority  study  design using a n ordinal  composite  overall  outcome (Desirability  of Outcome  
Ranking, DOOR, see 3.2.1  Primary  Outcome  Measures) —to test the hypothesis  that short  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
14 course (5 day) therapy  is superior  to standard  course (10-day) beta-lactam  therapy in children 
who have experienced early clinical  improvement of pneumonia.  
2.3 Potential  Risks and Benefits  
2.3.1  Potential  Risks 
The potential  risk of short  course therapy  is that clinical outcomes  may not be equivalent  to 
standard  course therapy.   Specificall y, the percent  of children with adequate clinical response 
(or in this case, no relapse of illness ) may be lower  in children  receiving  short  course  therapy.   
Adequate  clinical response can be defined  as resolution or substantial improvement  in clinical 
signs and symptoms (e .g., fever, cough, respiratory rate, work of breathing)  and the lack of 
need for additional antibiotic  therapy , additional contacts  with the health care system , or surgical  
procedures  for worsening pneumonia.  The magnitude of this risk is not well established, 
although  a study  from Israel suggests  it is small8; nevertheless, this degree  of risk will be 
evaluated during this trial.  
2.3.2  Known  Potential  Benefits  
If, as assessed by the primary  outcome,  short  course therapy  is superior  to standard course 
therapy,  short  course t herapy  will reduce antibiotic  exposure among  children with CAP.  The 
potential  benefits  of reduced antimicrobial  exposure involve  benefits  both to the individual  child 
and the population as a whole.    
Potential  benefits  to the individual  child include a simpler  course  of therapy,  a  lower  risk of an 
adverse event  associated with antibiotic  therapy  (e.g.,  antibiotic  associated diarrhea,  
Clostridium  difficile  infection)  and a lower  risk of becoming colonized with antibiotic  resistant  
bacteria.    
Potential  benefits  to the population include a lower  prevalence of colonization with pathogenic  
antibiotic  resistant  bacteria among  children treated for CAP.   Since  these  bacteria are 
transmissible,  a lower  prevalence of colonization among  children  treated  for CAP confers  a 
potential  lower  risk of colonization among all persons  in the population,  including  children and 
adults  regardless  of whether  they are treated with antibiotics.   
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
15 3 OBJECTIVES 
3.1 Study  Objectives 
 
Primary : 
1. To compare the composite overall  outcome ( Desirability  of Outcome  Ranking,  DOOR ) 
among  children  6-71 months  of age with CAP assigned to a strategy  of short  course  (5 
days)  vs standard  course  (10 days)  outpatient  beta-lactam  therapy  at Outcome  
Assessment Visit #1 (Study  Day 8 +/- 2 days ) 
  
Secondary : 
1. To compare the composite overall  outcome (DOOR)  among children  6-71 months  of age 
with CAP assigned to a strategy  of short  course (5 days)  vs standard  course (10 days)  
outpatient  beta-lactam  therapy  at Outcome  Assessment  Visit #2 (Study  Day 22 +/- 3 
days ) 
2. To compare the resolution of symptoms (a component of DOOR) among  children 6- 71 
months  of age with CAP assigned  to a strategy  of short  course (5 days)  vs standard 
course (10 days)  outpatient  beta-lactam  therapy  at Outcome Assessment Visits #1 and 
#2 
3. To compare the clinical response (a component  of DOOR)  among  children  6-71 months  
of age with CAP assigned to a strategy  of short  course (5 days)  vs standard course (10 
days)  outpatient  beta-lactam  therapy  at Outcome  Assessment Visits #1 and #2  
4. To compare solicited  events  (a component  of DOOR)  amon g children 6- 71 months  of 
age with CAP assigned  to a strategy  of short  course (5 days)  vs standard  course (10 
days)  outpatient  beta-lactam  therapy  at Outcome  Assessment Visits  #1 and #2 
5. To compare m edically  attended visits  to Emergency  Department s (ED) or outpatient  
clinics , hospitalizations , surgical  procedures , and receipt  of non-study  systemic 
antibiotic s (components  of the clinical response)  among  children  6-71 months  of age 
with CAP assigned to a strategy  of short  course (5 days)  vs standard  course (10 days)  
outpatient  beta-lactam  therapy  at Outcome  Assessment  Visits  #1 and #2 
Exploratory : 
1. To examine the robustness of results of DOOR comparisons when increasing the 
threshold in assigning different ranks due to differing numbers of days of antibiotic use 
from a one day difference to a two, three, four, or five day difference. 
3.2 S tudy  Outcome Measures 
3.2.1  Primary  Outcome  Measures  
 
The primary  endpoint/outcome measure is the DOOR  at Outcome  Assessm ent Visit #1. 
 
DOOR  is defined  as follows:   
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
16 I. Each  subject  is evaluated according  to the ordinal  composite outcome (See  Table 1 
below ) and assigned an outcome rank ranging from 1 -8. 
II. D esirability  of Outcome  Ranking  (DOOR ) is then assigned  according to two rules:  
(i) When  comparing  two subject s with different  ordinal  responses , the subject  with a 
better  ordinal  response  receives  a higher  rank.  
(ii) When  comparing  two subject s with identical  ordinal  responses , the subject  with 
fewer  days  of antibiotic  use receives  a higher  rank.  
 
The ordinal  composite outcome  involves  an assessment of whether  the subject  has an adequate  
clinical response and whether  they have experienced any solicited  events  as defined below.  
 
 
Table 1. Ordinal Outcome  
 Adequate  clinical  response1  
(Assessed  at Outcome  Assessment  Visits  
#1 and #2) Solicited  events3 
(Assessed  at Outcome  Assessment  Visits  
#1 and #2) 
1 Yes, with resolution of symptoms2 None  
2 Yes, with resolution of symptoms2 Mild (Grade  1) 
3 Yes, with resolution of symptoms2 Moderate  (Grade  2) 
4 Yes, with resolution of symptoms2 Severe  (Grade  3) 
5 Yes, with  persistent symptoms  of fever, 
tachypnea, or cough None or any grade  
6 No, with ED/clinic  visit but no hospitalization  None  or any grade  
7 No, with hospitalization  None  or any grade  
8 Death  from any cause  
1Adequate  clinical response is defined  as the absence of a medically attended visit to an ED or 
outpatient clinic or hospitalization for persistent or worsening pneumonia that occurs after 
randomization and receipt of at least one dose of study drug. 
• Persistent  or worsening pneumonia is defined  as receipt  of a non-study  systemic 
antibiotic  for pneumonia or treatment for a complication of pneumonia,  including  drainage  
of pleural  fluid,  placement  of a chest  tube,  video assisted thoraco scopic  surgery,  or 
thoracotomy  procedures.    
• Note: Receipt  of a non-study  antibiotic  will not be regarded  as satisfying  this definition  if it 
is related  to a new diagnosis that is unrelated  to the prior diagnosis  of pneumonia.  
 
2Resolution of symptoms is defined as the absence of all of the following:   
• Oral, rectal , axillary, or tympanic  temperature ≥ 38.3˚C  (100.9˚F) , confirmed by repeat 
measurement after at least 15 minutes,  in the 24 hours  preceding  the Outcome 
Assessment Visit or measured at the Outcome Assessment Vis it, unless  attributed  to a 
new process  that is unrelated to the prior diagnosis  of pneumonia;  
• Elevated respiratory  rate (RR >50 breaths/minute  for children  <24 months  of age and > 40 
breaths /minute  for children 24-71 months  of age) at the time of the Outcome  Assessment 
Visit; 
• Presence of cough grade 2 or 3 at the Outcome Assessment Visit , (defined in Table 2). 
 
3Solicited events  (Table 3) will be captured daily until Outcome Assessment Visit #2 ; thereafter, 
parents /legal guardians  will report symptoms based on memory aid and medical interview by 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
17 study staff. For those with multiple solicited events, the ordinal response table will be based 
upon the most severe solicited event.  
  
Table 2: Severity of Cough 
Symptom  Mild (Grade 1)  Moderate  (Grade 2)  Severe  (Grade 3)  
Cough  Occasional coughing 
(less than 4 times 
hourly)  Frequent coughing ( 4 or 
more times an hour], 
interferes with sleep ) Almost constant coughing 
(never free of cough), makes 
sleep nearly impossible  
 
Table 3. Solicited Events Grading  
Symptom  Mild (Grade 1) Moderate  (Grade 2) Severe  (Grade 3) 
Irritability  More  irritable  or fussy  
than usual  but can be 
consoled; no interference 
with smiling/playing  Irritability  or fussiness  that 
is difficult  to console and 
interferes  with smiling  and 
playing  Irritability  or fussiness  that 
lasts for more than 4 
consecutive hours  in a 24 
hour period  or cannot  be 
consoled  
Vomiting   1 episode/day   2-3 episodes/day   ≥4 episodes/day   
Diarrhea   Loose r than normal  stool s 
occurring 3-6 times/day  Looser than normal  stools  
occurring >6 times/day   Bloody  diarrhea,  or diarrhea  
that requires  medical  
intervention, laboratory  
testing,  or hospitalization  
Allergic  
Reaction  Localized  rash or  
pruritus  without  rash Diffuse  rash 
(maculopapular  or 
urticarial)   Generalized  rash consistent  
with Stevens -Johnson 
Syndrome,  erythema 
multiforme , or toxic 
epidermal  necrolysis;  
anaphylaxis;  or  
angioedema   
Stomatitis  Oral lesions associated 
with parenteral report of 
mild oral discomfort   Oral lesions associated with 
difficulty  swallowing,  but 
able to  eat and drink  Oral lesions associated with 
inability to swallow  solids  or 
liquids;  requires  medical  
intervention, IV fluids,  or 
hospitalization  
Candidiasis  Mild mucocutaneous  
candidiasis  or diaper  
dermatitis,  with no 
treatment  or topical  
treatment  only Mode rate mucocutaneous  
candidiasis  requiring  oral 
antimicrobial treatment  Severe  mucocutaneous  
candidiasis;  requires  medical  
intervention, intravenous  
treatment,  or hospitalization  
 
3.2.2  Secondary  Outcome  Measures 
Secondary  outcome measures  include:  
1. DOOR  at Outcome  Assessment Visit #2. 
2. Resolution of symptoms (a component of DOOR) at each outcome assessment visit, 
defined as the absence of fever, tachypnea, or cough of grade 2 or higher.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
18 3. Adequate clinical response rates (a component of DOOR) at each outcome assessment 
visit, defined as the absence of a medically attended visit to an ED or outpatient clinic or 
hospitalization for persistent or worsening pneumonia that occurs after randomization and 
receipt of at least one dose of study drug.  
4. Frequency of solicited events at each outcome assessment visit, as listed in Table 3.  
5. Medically  attended visits  to ED or clinic ; hospitalizations ; surgical  procedures ; and receipt  
of non-study  systemic antibiotics  for persistent or worsening pneumonia  (as defined 
above) at each outcome assessment visit 
i. Individual event types (e.g., medical visits , hospitalizations , surgical procedures , 
and receipt of non -study systemic antibiotics) will be compared between treatment 
groups.  
6. Medically attended visits to ED or clinic; hospitalizations; surgical procedures; and receipt 
of non -study systemic antibiotics  for all causes  at each outcome assessment visit   
i. Individual event types (e.g., medical visits , hospitalizations , surgical procedures , 
and receipt of non -study systemic antibiotic ) will be compared between treatment 
groups.  
3.2.3  Exploratory Outcome Measures  
 
1. DOOR at Outcome Assessment Visits #1 and #2, when increasing the threshold in 
assigning different ranks due to differing numbers of days of antibiotic use from a one 
day difference to a two, three, four, or five day difference.   
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
19 4 STUDY DESIGN  
This is a multi-ce nter, randomized, double- blind, placebo- controlled, superiority clinical trial 
evaluating short course (5 day) vs. standard course (10 day) of oral beta -lactam antibiotic 
therapy ( amoxicillin, amoxicillin -clavulanate, cefdinir) for treatment of CAP  in children 6- 71 
months of age who have clinically improved  prior to enrollment. The study will randomize 
approximately 400 enrolled subjects to one of the two study arms (approximately 200 children in 
each arm)  in order to reach 360 subjects  completing O utcome Assessment Visit  1. Subjects will 
be randomized (1:1) to receive either a standard course of the initially prescribed antibiotic (10 
days) or a short course of the initially prescribed antibiotic (5 days) plus 5 days of matching 
placebo.   
 The study will recruit  potential  subjects  from children who are diagnosed  with CAP and who are 
initiated  on oral beta-lactam  therapy  (amoxicillin,  amoxicillin -clavulanate,  cefdinir)  by healthcare 
providers  in EDs, outpatient  clinics , and urgent  care center s at the study  sites. Day -5 is defined 
as the date on which  oral beta -lactam therapy is initiated for a diagnosis  of CAP.  Potential  
subjects  will be identified  at any time following  clinical diagnosis  of pneumonia.  These subjects  
will be assessed for eligibility  and enrolled on Day -3 to -1 of their initially  prescribed  oral beta-
lactam  therapy .  Subject s may also be enrolled on Day 1 (the first day of receipt of study agent) 
provided they have not yet received any doses of the healthcare provider -prescribed antibiotic 
therapy for that day.   
 A Schedule of Events  is provided in Appendix  A.  
 Visit  1:  Enrollment  Visit . Subjects  who meet  the eligibility  criteria , and whose parent/guardian 
consent s for participation  in the study,  will complete an Enrollment  Visit on Day -3 to -1. 
Subjects  satisfying  the inclusion  criteria  with no exclusion  criteria  will be enrolled and 
randomi
zed. Enrolled subjects  will continue to receive  the initially  prescribed antibiotic  through  
Day -1.  The subjects’ parents/guardians wi ll be instructed to contact study personnel if their 
child develops fever  or worsening respiratory symptoms  (worsening cough, increased work of 
breathing, any other concerning symptoms in the parents’ estimation) following enrollment .  
 Randomization:   Enrolled subjects  will be randomized to short  vs. standard course therapy  at a 
1:1 ratio,  with stratification  by 1) age group  (<24 months  vs. 24-71 months ), 2) initially 
prescribed antibiotic  (amoxicillin vs. amoxicillin -clavulanate vs. cefdinir), and 3)  treatment  site 
(emergency  department  vs. outpatient  clinic /urgent  care facility ). 
 Intervention:   Subjects  will continue on the initially  prescribed antibiotic  through  Day -1, until 
they have completed  5 days  (i.e., 5 scheduled doses of once daily medication, 10 scheduled 
doses  of twice daily medication) of antibiotic  therapy  [e.g., if a subject takes the first dose of 
antibiotic in the afternoon of Day -5, the first dose of study agent would occur on the afternoon 
of Day 1, providing 10 total scheduled doses of a twice daily prescribed antimicrobial] . The first 
day of receipt  of study  agent  will be Day 1.  Subjects  assigned  to standard course  therapy  will 
receive 5 additional days  (10 doses)  of the same  initially  prescribed antibiotic , with standardized 
twice -daily dosing .  Subjects  assigned  to short  course therapy  will receive 5 more  days  (10 
doses)  of a matching placebo.   Both the study agent and placebo may appear different than the 
commercial formulat ion the child originally received. The placebo will appear  indistinguishable in 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
20 color,  taste,  thickness,  and consistency  as the active antibiotic the child would otherwise receive 
in the study. The study  product  will be labeled with a numerical  code  that masks site 
investigators,  site staff,  parent(s)/guardian(s)  and children to the formulation.  
 
Follow -up and Assessment  of Endpoints:   Subjects  will be scheduled for the following  
assessment visits:  
 Visit 2: Outcome  Assessment  Visit #1, Day 6 to 10 (1-5 days  after completing  the study  agent ). 
Subjects  will be evaluated for the components  of the composite overall  outcome, which  includ e 
the adequacy  of the subject’s  clinical response ; persistence of symptoms of fever, tachypnea, or 
cough ; the occurrence of any solicited  events ; and the duration of antibiotic  therapy  (both  study  
product/placebo and any additional oral or parenteral  antibiotic  therapy  prescribed by study  or 
non-study  providers) . 
 Visit 3: Outcome  Assessment  Visit #2, Day 19 to 25 (14-20 days  after completing  the study  
agent ). Subjects  will be evaluated for the components  of the composite overall  outcome, which  
includ e the adequacy  of the subject’s clinical response; persistence of symptoms of fever, 
tachypnea, or cough; the occurrence  of any solicited events ; and the duration of antibiotic  
therapy  (both  study  product/placebo  and any additional  oral or parenteral  antibiotic  therapy  
prescribed  by study  or non-study  providers) . 
 Subjects  who are identified as having an inadequate clinical response  prior to Outcome  
Assessment Visit #1 will be asked to complete Outcome  Assessment Visits  #1 and #2 in order  
to evaluate the occurrence of any solicited  events  and the duration  of antibiotic  therapy  (both  
study  product/placebo  and any additional oral or parenteral  antibiotic  therapy  prescribed by 
study  or non-study  providers) .  
 
Subjects will be invited to contribute oropharyngeal and stool specimens at specified times throughout the study for future use (see Appendix  A, Schedule of Events).  Addit ional informed 
consent will be obtained for future use sample collection.  
 
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
21 5 STUDY ENROLLMENT  AND  WITHDRAWAL  
Subjects who are diagnosed with CAP in EDs, urgent care facilities, and clinics will be screened 
for eligibility .  Screening will continue until 400 subjects are enrolled cumulatively across all the 
study sites.  The study will recruit potential subjects from children who are diagnosed with CAP 
and who are initiated on antibiotic therapy using oral beta -lactam therapy (amoxicillin, 
amoxicillin -clavulanate, cefdinir) by healthcare providers in EDs, outpatient clinics, and urgent 
care centers at the study sites. Potential subjects will be identified at any time following clinical 
diagnosis of pneumonia. Other forms and/or mechanisms of recruitment may also be used. The 
local IRB will approve recruitment materials prior to use.  
Subject Inclusion and Exclusion Criteria must be confirmed  by a study clinician licensed to make 
medical  diagnoses .  
No exemptions are granted on Subject Inclusion/Exclusion Criteria in DMID- sponsored studies. 
Questions  about eligibility will be directed toward the DMID Medical Officer.  
5.1 Subject  Inclusion  Criteria  
Eligible  subject s may be included in the study  if they meet  ALL of the following  criteria  at 
the Enrollment  Visit  (Day  -3 to -1): 
1. Age 6 – 71 months  
2. Provider  diagnosis  of CAP and prescription  of antibiotic  therapy  with amoxicillin1, 
amoxicillin -clavulanate1, or cefdinir2 
1 amoxicillin or amoxicillin -clavulanate prescribed at a minimum  amoxicillin dose 
of 60 mg/kg/day  
2 cefdinir prescribed at a minimum dose of 10 mg/kg/day  
3. Parental  report  of clinical improvement3 
3 based on lack of either subjective or known fever (temperature ≥38.3°C in the 
preceding 24 hours ); current  respiratory rate no greater than 50 breaths/minute 
(<2 years of age) or 40 breaths/minute ( > 2 years of age); and current grade of 
cough <3.  
4. Ability  of a parent  or guardian to understand and comply  with the study  
procedures  and be available for all study  visits  
5. Signed written  informed consent  by a parent  or guardian 
5.2 Subject  Exclusion  Criteria  
Subject s will be excluded from  the study  if they meet  ANY of the following  criteri a: 
1. Treatment  with any systemic antib iotic therapy  within 7 days  before  the diagnosis  
of CAP 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
22 2. Initial therapy for CAP with combination antibiotic therapy4 
4 amoxicillin,  amoxicillin/clavulanate or cefdinir  plus one or more  additional  oral, 
intravenous, or intramuscular antibiotic s 
3. History  of anaphylaxis  or severe drug allergy  to amoxicillin , if prescribed 
amoxicillin  or amoxicillin/clavulanic  acid;  or oral cephalosporin antibiotics  (except  
cefaclor ), if prescribed cefdinir  
4. Presence of concomitant  bacterial  infection  that requires  >5 days  of antibiotic  
therapy  
5. Radiographic  findings  (where applicable) of complicated pneumonia5  at 
presentation or any subsequent chest radiograph up to the time of enrollment  
5 Clinically significant pleural effusion, lung abscess, or pneumatocele 
6. Hospitalization6 for pneumonia during Day -5 to -1 of antibiotic  therapy  for CAP 
6Subjects who require serial clinical assessments, but are discharged within 24 
hours will not be considered hospitalized and will not satisfy this exclusion 
criterion.  
7. Pneumonia due to S. aureus  or group  A streptococcus  documented  by positive  
blood culture  or PCR, at the time of enrollment.  
8. History of pneumonia within the previous 6 months   
9. History of persistent asthma7 within the previous 6 months or current acute 
asthma exacerbation8 
7 Persistent asthma is defined as receiving daily asthma maintenance therapy 
such as inhaled corticosteroids, cromolyn, theophylline, or leukotriene receptor 
antagonist s.  
8 Acute asthma exacerbation is defined as receiving concomitant bronchodilator 
therapy and systemic corticosteroids.  
10. Provider -diagnosis of aspiration pneumonia, bronchiolitis, or bronchitis .  
11. Surgery  or other  invasive  procedures  of the upper  or lower  airway  (e.g.,  
bronchoscopy,  laryngoscopy)  with general  anesthesia or hospitalization ≤7 days  
before  diagnosis  of CAP 
12. History  of an underlying  chronic  medical  condition9  
9 including chronic  heart  disease, chronic  lung disease ( except asthma) ,congenital  anomalies  of 
the airways  or lung, cystic fibrosis , chronic  renal  disease including nephrotic  syndrome,  protein-
losing  enteropathy  of any cause,  severe malnutrition,  neurocognitive disorders , metabolic  
disorders  (including phenylketonuria), or genetic disorders (note: genetic  syndromes such as 
Down  syndrome  and Edwards  Syndrome are excluded; however, c hildren with  genetic  disorders 
(e.g., hemophilia) but who do not have a genetic  syndrome  may not satisfy this particular 
exclusion criterion;  it is important that children with such genetic disorders do not have 
symptoms and/or comorbidities that would pose additional risk to them nor jeopardize the 
adequacy of study assessments.” ) 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
23 13. History  of a condition that compromises  the immune  system10  
10 HIV infection,  primary  immunodeficiency,  anatomic  or functional  asplenia; 
receipt  of a hematopoietic  stem  cell or solid organ  transplant  at any time; receipt  
of immunosuppressive therapy  including chemotherapeutic  agents , biologic  
agents , antimetabolites  or radiation therapy  during  the past 12 months ; or daily 
use of systemic corticosteroids  for more  than 7 consecutive days  during the past 
14 days . 
14. Any other  condition that in the judgment  of the investigator  precludes  
participation because it could a ffect the safety  of the subject  
15. Current  enrol lment  in another  clinical trial of an investigational  agent  
16. Previous  enrollment  in this trial  
5.3 Treatment  Assignment  Procedures  
5.3.1  Randomization  Procedures 
 
Per International  Conference on Harmonisation  (ICH)  guideline E6: Good  Clinical Practice 
(GCP),  screening  records  will be kept at each  participating site to document  the reason why an 
individual  was screened,  but failed  trial entry  criteria.   The reasons  why individuals  failed  
screening  will be recorded on screening  logs maintained by  each site.  
 
Once consented  and upon  entry  of demographic  data and confirmation  of eligibility  for this trial, 
the subject  will  be enrolled.   Subjects  will be assigned  to either  placebo or active  study  drug (the 
same antibiotic  that they were  prescribed for the first 5 days  of treatment). After  a subject  is 
enrolled,  they will be given  a random  treatment  assignment  of study  product  to either  short  
course or standard course  therapy.  Randomization to short vs. standard course therapy will be 
at a 1:1 ratio (approximately 200 subjects per treatment group). Subjects will be stratified by age 
group <24 months vs. 24 -71 months), type of initial antimicrobial therapy, and initial treatment in 
an ED or outpatient clinic/urgent care center.  
 Enrollment  of subjects  will be performed online using  AdvantageED C.  The list of randomized 
treatment assignments will be prepared by statisticians at The Emmes Corporation and included 
in The Emmes Corporation’s Internet Data Entry System (IDES). IDES will assign each 
volunteer a treatment code from the list  after the necessary data have been entered into the 
system. A designated individual at each site will be provided with a treatment key, which links 
the treatment code to the actual treatment assignment, which will be kept in a secure place.  
 
Instructions for subject enrollment are included in the Manual of Procedures (MOP). Manual 
back -up randomization procedures are provided in the MOP for use in the event that the site 
temporarily loses access to the Internet or the online enrollment system is unavailable.  
5.3.2  
Masking Procedures  
This is a double- blind clinical trial. The  study  subjects  and their parents/guardians,  investigators,  
and study  team staff will remain blinded to study  treatment  assignment  throughout  the study.  
The subjects  and their families,  investigators,  and study  team  staff w ill not be blinded to which  of 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
24 the three  antibiotics  (amoxicillin,  amoxicillin -clavulanate,  cefdinir)  the subject  was initially  
prescribed.   
 
The study  product s and placebo will be prepared  by the unblinded site Research Pharmacist . 
Only the preparing  pharmacist  will be aware of the study  product  bottle assignments.  For 
subjects  randomized to standard  course  therapy,  the pharmacy  will provide  the same  
medication prescribed initially . For subjects  randomized to short course therapy,  the pharmacy  
will provide a placebo that resembles the appearance (color  and texture),  flavor,  and 
consistency  of the active  study  product . All study  product s will be packaged  with an identical  
appearance.   Additional details regarding dispensing procedures will be included in the protocol -
specific MOP.   
 
The study  product  will be labeled with a numerical  code that masks site investigators,  site staff,  
parent(s)/guardian(s)  and children to the formulation.  The unblinded site Research Pharmacist 
will be the only person to perform the unmasking if needed.  Additional details regarding labeling procedures will be included in the protocol -specific MOP.  
 
During  the consenting process  it will be explained  to the parents  of any potential  subjects  that 
the study  product  (treatment  or placebo)  that will be provided for administration  after Day 5, may 
or may not taste  exactly  the same  as the originally  prescribed medication,  and that the look and 
smell may be slightly  different  because  it might  be supplied by a different  manufacturer  than that 
of the in 
itially  prescribed antibiotic . Parents  will also be instructed that the amount  or frequency  
of the prescribed  study  product  has been made uniform  across all study  groups;  therefore,  the 
amount /frequency  may be different  than originally  prescribed by their provider  (e.g.,  receipt  of 
once daily cefdinir  is not excluded,  but upon  study  entry,  those  subjects  will receive either  twice  
daily cefdinir  or placebo).   
5.3.3  Reasons for Withdrawal  
 
Subject  Withdrawal  
Subjects’  parents/guardians  may voluntarily  withdraw  their consent  for study  participation at any 
time and for any reason, without  penalty.  
 
A subject  may withdraw  or be withdrawn from the study  for any of the following  reasons:  
• W ithdrawal  of consent  
• Subject  lost to follow -up 
• Termination  of the study  
• Any new information becomes available that makes further participation unsafe.  
 
Subjects who wish to withdraw from further study participation will be asked to continue to participate in follow -up visits. At the time of withdrawal, subjects will undergo an early termination 
visit, if they are not willing to participate in the remaining follow -up visits . 
 
Discontinuation  of Treatment  
A subject may be discontinued from treatment and continue to be followed if any of individual 
halting rules, as defined in Section 9. 5.2, are met . 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
25 5.3.4  Handling of Withdrawals   
 
The primary  reason  for withdrawal  from the study  will be recorded on the Study  Status  data 
collection  form.   Parents/guardians  will be encouraged  to complete the Early  Termination Visit, 
as listed  in Section 7.5.  Unless  they expressly  state  that they wish to have no additional follow -
up or data collection,  subjects  who withdraw  from the study  will receive a follow -up phone call 
approximately  one week  after their withdrawal .  This will allow  the site to assess the status  of 
the subject  and determine  if any medical  follow  up care was sought.   Although  subjects  are free 
to withdraw  at any time or may be withdrawn by the site PI or appropriate sub-investigator  at 
any time,  subjects  will be encouraged  to remain  in this study  for follow -up assessments (may  be 
by telephone rather  than in person)  continuing  through  approximately  1 month after study  
treatment.   
 
Every attempt  will be made to follow  all ongoing solicited  events  or serious  adverse events,  as 
well as new-onset  chronic  medical  conditions , to resolution or until the subject’s condition 
becomes stable.   
Subjects  who discontinue treatment  will be followed  according  to the study  pr
 otocol  and will not 
be replaced.    
5.3.5  Termination  of Study   
 
The National  Institute  of Allergy  and Infectious  Diseases  (NIAID),  the IRB of record , or the FDA 
may discontinue the study  at any time.  Should the study  be discontinued prior to completion,  
any subjects  on study  will complete  study  visits,  if medically  appropriate but no new subjects  
would  be enrolled.    
 
Although  the study  Sponsor  has every  intention of completing  this study,  it reserves  the right to 
terminate this study  at any time for clinical or administrative  reasons.  Reasons  for termination 
include,  but are not limited  to, study  closure  due to DSMB  review  and recommendation and at 
the discretion of DMID.  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
26 6 STUDY INTERVENTION/INVESTIGATIONAL  PRODUCT 
6.1 Study Product Description  
 
Amoxicillin  
Amoxicillin, USP is a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of 
bactericidal activity against  many gram -positive and gram -negative microorganisms.  Amoxicillin 
is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of 
active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the death 
of the bacteria.  
 Amoxicillin -Clavulanate 
Amoxicillin -Clavulanate is an oral antibacterial combination consisting of semisynthetic antibiotic 
amoxicillin and the beta- lactamase inhibitor, clavulanate potassium.  Clavulanic acid is 
particularly active against the clinically important plasmid- mediated beta- lactamases frequently 
responsible for transferred drug resistance to penicillins and cephalosporins.  
 
Cefdinir  
Cefdinir is an extended- spectrum, semisynthetic cephalosporin.  Bactericidal ac tivity of cefdinir 
results from inhibition of cell wall synthesis and is stable in the presence of some, but not all, beta- lactamase enzymes. As a result, many organisms resistant to penicillins and some 
cephalosporins are susceptible to cefdinir. 
6.1.1  Acquisition  
Amoxicillin, Amoxicillin -Clavulanate, and Cefdinir will be obtained by the DMID Clinical Materials 
Services  (CMS, Fisher BioServices).  The matching placebo for each active drug will be will be 
prepared by a compounding pharmacy and stored at the DMID CMS.  
 
The compounding, filling, packaging and labeling of study drug placebos will be done according 
to applicable regulatory requirements.  All active study drugs and placebos will be acquired through the DMID C MS. 
 Study product (amoxicillin, amoxicillin -clavulanate, cefdinir and matching placebos) will be 
shipped from the DMID C MS to the study site upon request and approval by DMID.  
6.1.2  Formulation, Packaging, and Labeling  
6.1.2.1  Amoxicillin  
Amoxicillin will be supplied as an oral powder for suspension in the following strength:  400mg/ 
5mL packaged in 100mL bottles.  The 400mg/5mL strength contains 400mg of amoxicillin as the 
trihydrate in each 5mL of reconstituted suspension.  
6.1.2.2  Placebo for Amoxicillin  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
27 Placebo will be supplied as matching liquid.  In order to maintain the blind, the liquid placebo will 
be formulated for the same appearance (color and texture), flavor and consistency as the active 
study drug and will be provided in 100mL bottles. 
6.1.2.3  Amoxicillin -Clavulanate 
Amoxicillin -clavulanate will be supplied as an oral powder for suspension in the following 
strength:  400mg/ 5mL packaged in 100mL bottles.    The 400mg/ 5mL strength contains 400mg 
of amoxicillin and 57mg of clavulanic acid as a potassium salt in each 5mL of reconstituted 
suspension.  Each 5mL of the 400mg/ 5mL strength contains 0.29mEq of potassium.  The 
400mg/ 5mL formulations contain aspartame and should not be used by phenylketonurics.  
6.1.2.4  Placebo for Amoxicillin -Clavulanate  
Placebo will be supplied as matching liquid.  In order to maintain the blind, the liquid placebo will 
be formulated for the same appearance (color and texture), flavor and consistency as the active 
study drug and will be provided in 100mL bottles. 
6.1.2.5  Cefdinir  
Cefdinir will be supplied as a white to off -white oral powder for suspension in the following 
strengths:  125mg/ 5mL and 250mg/ 5mL packaged in 100mL bottles.  The 125mg/ 5mL 
strength contains 125mg of cefdinir in each 5mL of reconstituted suspension.  The 250mg/ 5mL 
strength contains 250mg of cefdinir in each 5mL of reconstituted suspension.   Each 5mL of the 
250mg/ 5mL strength contains 1.37g of sucrose and each 5mL of the 125mg/5mL strength contains 1.5g of sucrose. Certain formulations from different manufacturers may contain up to 
2.86g of sucrose per 5mL.  
The lower strength (125mg/ 5mL) will be used in the lower weight bands (or as originally 
prescribed prior to enrollment) and the higher strength (250mg/ 5mL) will be used in the higher 
weight bands (or as originally prescribed prior to enrollment) as described in the protocol -
specific MOP.  
6.1.2.6  Placebo for Cefdinir  
Placebo will be supplied as matching liquid for each of the active strengths provided.  In order to 
maintain the blind, the liquid placebo will be formulated for the same appearance (color and 
texture), flavor and consistency as the active study drug and will be provided in 100mL bottles.   
6.1.2.7  Packaging and Labeling 
 
The active study drug will be supplied in their original manufacturer’s bottles.  The placebo supplied for each active study drug will be filled and packaged by the compounding pharmacy.  
Each container will also be labeled in compliance with applicable regulatory requirements, 
including the FDA -required cautionary statement “Caution-  New drug -Limited by Federal (or 
United States) Law to Investigational Use Only.” As per Section 6.2.2, at the time of study 
product preparation, the site pharmacist will transfer the contents of the active and placebo into 
identical containers and affix with blinded labels for dispensing to the subject.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
28 6.1.3  Product Storage and Stability  
6.1.3.1  Amoxillin  
Store dry powder at 20˚C  to 25˚C (68˚F to 77˚F)  [See USP Controlled Room Temperature]  for 
unreconstituted powder   
Upon reconstitution, when stored under refrigeration or room temperature, any remaining or 
unused portion must not be used after 14 days.  Refrigerated storage is preferred, but not 
required.  
6.1.3.2  Placebo for Amoxicillin  
Store the s uspension at 2°C to 8°C. 
To maintain the blind, upon dispensing, parents/caregivers will be given the same storage 
instructions as the active drug.  
6.1.3.3  Amoxicillin -Clavulanate 
Store dry powder  at 20˚C to 25˚C (68˚F to 77˚F)  [See USP Controlled Room Temperature ]. 
Upon reconstitution, the suspension must be stored under refrigeration and any remaining  or 
unused portion must not be used after 10 days   
6.1.3.4  Placebo for Amoxicillin -Clavulanate  
Store the suspension at 2°C to 8°C. 
To maintain the blind, upon dispensing, parents/caregivers will be given the same storage 
instructions as the active drug.  
6.1.3.5  Cefdinir  
Store dry, unsuspended powder at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room 
Temperature].  
Upon reconstitution, the suspension must be stored at room temperature  and any remaining  or 
unused portion must not be used after 10 days . 
6.1.3.6  Placebo for Cefdinir  
Store the suspension at 2°C to 8°C. 
To maintain the blind, upon dispensing, parents/caregivers will be given the same storage 
instructions as the active drug.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
29 6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  
6.2.1  Dosage 
Subjects  will complete five days of their originally prescribed antibiotic and then take 5 days of 
the study product, as follows:  
Amoxicillin and Amoxicillin -Clavulanate  
Amoxicillin and Amoxicillin -Clavulanate will be dosed based on the amoxicillin component as 
80-100 mg/kg/day (maximum 2000 mg/day ) divided twice daily.  
The matching placebo will be dosed at the same volume calculated for the active dose.  
Cefdinir  
Cefdinir will be dosed as 12- 16 mg/kg/day (maximum 600mg/ day)  divided twice daily.  
The matching placebo will be dosed at the same volume calculated for the active dose.  
6.2.2  Preparation  
The site Research  Pharmacist must  be unblinded and will prepare the active and placebo study 
products for dispensing to the subject.  
Instructions for reconstitution of each active drug will be provided in the protocol -specific MOP.  
Upon reconstitution, active amoxicillin, amoxicillin -clavulanate, and cefdinir will be tran sferred 
from their original commercial containers  into new containers strictly for blinding/masking 
purposes.   The matching placebo liquid will be transferred into identical containers to maintain 
the blind.  
Additional details regarding subsequent labeling, preparation of kits, and procedures for 
dispensing or administration of study product will be described in the protocol -specific MOP.  
6.2.3  Administration  
All active and placebo study products will be orally administered via oral dosing syringe or dosing cup. For older children in whom a dosing cup is preferred, parents will be instructed to 
measure the drug in the oral dosing syringe prior to transferring to the dosing cup.  
6.3 Modification of Study Intervention/Investigational Product for a Participant  
No modifications of study product are planned at this time.  If a subject experiences any 
individual halting rule, as defined in Section 9. 5.2, they will be taken off of the study drug.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
30 6.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
After receipt of the study product, the site Principal Investigator (PI) is responsible for 
distribution and disposition of these study products, and has ultimate responsibility for drug accountability. As this is a blinded study, t he site PI will delegat e this responsibility to the 
unblinded site pharmacist.  Study product records must be maintained and document logs of receipt, accountability, and storage temperature conditions. These study product accountability 
and dispensing logs must be maintained in the study file.  Upon completion of the study and 
after the final monitoring visit, unused study product will be retained until monitored and 
released for disposition as per the Sponsor.  
6.5 Assessment of Subject Compliance with Study Intervention/Investigati onal 
Product  
The investigator will maintain records documenting all study product s administered to each 
subject for the entire study period. Subjects will be asked to complete a memory aid and bring 
their study product containers. The memory aid will be used to record daily study medication 
taken, concomitant medications (e.g., pain medication),  temperature , solicited events, and 
presence of cough. The study coordinator/investigator will document any missed doses of study medication and provide counseling per study sites’ routine procedures to promote compliance 
with study medication. The information on the memory aid will be recorded on a source document, but the memory aid will not be collected from the subject.  If a subject ’s memory aid 
is not  available, study medication compliance will be obtained by parental  interview. The study 
coordinator/investigator will record how study drug compliance information was obtained.   In 
addition, study product containers will be collected.  Study product which has been dispensed  
and has been returned to the pharmacy should be documented in the study product 
accountability log and discarded as biohazardous waste.  
6.6 Concomitant  Medications/Treatments  
Administration of any medications, therapies, or vaccines including  dose and frequency, will be 
recorded on the appropriate data collection form.  Concomitant  medications will include all 
current medications and medications taken within 30 days prior to signing the informed consent form through the last study visit or early termination. Prescription and over -the-counter drugs will 
be included, as well as herbals, vitamins, and supplements.  
Use of new medication should prompt evaluation for the presence of a new diagnosis of chronic 
medical disease or condition.  
Medications that might interfere with the evaluation of the study product or may compromise participant safety should not be used during the study. Medications in this category include the 
prohibited medications per the Subject Exclusion Criteria (see Section 5. 2). In addition, the site 
principal investigator or appropriate sub- investigator may identify ot her medi cations that should 
not be used due to a risk to subject safety . 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
31 7 STUDY SCHEDULE 
7.1 Screening  
 
Each  study  site will determine the most  efficient  procedures  to identify  potentially  eligible  
subjects  from primary  care clinics,  urgent  care centers,  and emergency  departments  affiliated  
with the study  clinical trial centers.  Providers  will be informed about  the study  and provided with 
site-specific SCOUT -CAP provider  information  pamphlets  summarizing  the study  design and 
participant  eligibility  criteria.  Providers  may also be asked to alert their patients  about  their 
practice’s  participation  in the SCOUT -CAP study,  instructing them  that study  personnel  may 
contact  them  to discuss potential  research  opportunities.   
 
The identification of potentially  eligible  subjects  will vary by site and practice  setting and will 
include direct  communication with providers,  review  of clinical intake  logs,  and electronic  health 
record  (EHR)  alerts  that automatically  screen for new pneumonia cases  from medical  records.   
 
Once a potentially  eligible  subject  with the diagnosis of CAP  is identified, study  staff will first 
contact  the treating clinic  to confirm  willingness  to have the patient  participate in the study.  For 
subjects  deemed potentially  eligible,  study  staff will attempt  to contact  the parent(s)/guardian(s)  
by telephone. If the parent(s)/guardian(s)  are contacted  successfully,  the study  staff may use 
the 
telephone contact guide (see MOP) . Study  staff will explain  the study  protocol  and describe 
the inclusion/exclusion criteria.  Study  staff will answer  any questions  and concerns  the 
parent(s)/guardian(s)  may have.  If the parent(s)/guardian(s)  are interested  in the study,  study  
staff will schedule the Enrollment  Visit on Day -3 to Day -1 of antibiotic  therapy.   
 Parent s/caregivers  of potential  subjects  who express  interest  in participation will be contacted 
again by study staff prior to the Enrollment  Visit to confirm  the appointment  time and location  
and to assess the presence  of ongoing  symptoms  such as fever,  respiratory rate, and cough.  If 
fever, elevated respiratory rate, or Grade 3 cough are present,  the visit may be rescheduled for 
a later day, but no later than before  receipt  of the first dose  of their initially  prescribed  antibiotic  
on the sixth consecutive calendar  day of treatment.   In all instances,  the parent/guardian will be 
instructed to continue administration  of original  antibiotic  as instructed by the treating  clinician  
until the Enrollment  Visit.   
7.2 Enrollment/Baseline  
At the Enrollment  Visit,  study  staff will obtain written  informed consent  from the 
parent(s)/guardian(s)  for the primary  study  and request consent for collection of throat swabs 
and stool specimens for future use.   Declination  to participate in collection of future use samples  
will not affect  participation in the primary  study.  After  the parent/guardian has had the 
opportunity  to ask questions  and
  has signed the informed consent  document,  the following 
activities will be performed by the study staff :  
• Eligibility criteria will be reviewed;  
• A complete medical history  and sociodemographic data will be obtained by interview 
with the subject’s parent(s)/legal guardian; 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
32 • A physical assessment will be performed to determine general appearance, hydration 
status; vital signs, including temperature, heart rate,  and respiratory rate; an 
assessment of work of breathing; and presence of skin rash;  additionally, if indicated by 
the physical assessment or medical history, a physical examination by a study clinician 
may occur;  
* Note: physical assessments may be performed by physicians, advanced practice nurses, physician assistants, or nurses.  
• An initial assessment of clinical response will be obtained to i nclude report of subjective 
fever, maximum temperature  in the past 24 hours (if taken), and an assessment of 
improved activity and appetite since initiating antibiotic therapy;  
• All concomitant medications taken within 30 days of signing the informed consent form 
will be recorded;  
• Subjects  who meet eligibility criteria will be enrolled in AdvantageEDC
SM and randomly  
assigned to one of two arms: standard course therapy (5 days of active medication) vs. short course therapy (5 days of matching placebo) ; 
• Study product will be dispensed and study staff will review the study product with the 
subject’s family and review the study product storage and  dosing instructions;  
• Subjects will be provided with a memory aid and other study -related materials to record 
daily temperature, solicited events, concomitant medications, presence of cough, and 
daily dose administration. Parents will be instructed that any temperatures over 100.9˚F 
should be repeated 15 minutes later in the same manner as the initial temperature. 
Study staff will instruct the parent/guardian to complete the memory aid  in order to 
document adherence and to bring the medication bottle with them to the Outcome 
Assessment Visit #1. Study staff will also review the memory aid used to assess specific, 
solicited events ; 
• Collection of a throat swab specimen  if contributing future use samples;  
• Dispense containers  for collection of  a stool specimen, if participating in future use 
portion of the study.  
Since the Enrollment Visit will occur during Day 3- 5 of treatment (Day -3 to -1), the subject will 
be instructed to complete the originally prescribed medication through Day -1 (after receipt of 
the last dose of the originally prescribed medication on the fifth consecutive calendar day of 
treatment) and to start study product on Day 1.  
Parents will be educated at the time of their child’s enrollment in the study about prompt and 
adequate treatment for recurrence of symptoms or solicited events. The subject’s 
parent/guardian will be instructed to contact their primary care provider as soon as possible in 
the event of worsening respiratory status, recurrence of fever, or for other concerns. 
Parents/guardians will also be asked to contact study personnel in the event of clinical deterioration (i.e., medical visit or hospitalization for pneumonia) or for any severe solicited 
events.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
33 Study personnel will be available at each site for urgent issues related to the study or for 
communication with primary care providers who may have questions about the study.  
Subjects who do not meet eligibility  criteria or decline consent will be instructed to continue their 
initially prescribed antibiotic unless otherwise advised by their treating cl inician.  
7.3 Follow -up  
 
Visit 2: Outcome  Assessment  Visit #1, Day 6-10 
Subjects  will be seen for a follow -up visit on Day 6 -10.  Prior  to this visit, study  staff will, when 
possible,  make  a preliminary  assessment  of the clinical response using  the electronic  health 
record  to determine  whether  any of the following  events  have occurred  after randomization and 
anticipated receipt  of at least  one dose  of study  agent . 
• The subject  had a medically  attended  visit to an ED, urgent  care,  or clinic ; 
• The subject was hospitalized;  
• The subject  received non-study , systemic antibiotic  therapy;  
• The subject  underwent  drainage  of pleural  fluid, placement  of a chest tube,  or video 
assisted thoraco scopic  surgery.    
At the follow -up visit, study  staff will complete the following  procedures:  
• Medical  history  to determine whether  medically  attended visits,  receipt of non-study  
systemic antibiotics , or surgical  procedures  have occurred ;  
• Assessment of adequate  clinical improvement  as indicated by a parental  report  of lack of 
rectal , tympanic,  axillary or oral temperature ≥ 38.3°C  or 100.9°F , normalization of 
respiratory  rate for age (< 50 breaths/minute for children <24 months  of age and <40 
breaths/minute for children 24-71 months  of age), and grading of cough . 
• Physical  assessment  to determine vital signs ( temperature , pulse and  respiratory  rates) 
and physical assessment (general appearance, hydration status, work of breathing, presence of skin rash);  
• Review  of the subject’s memory  aid to assess and record any solicited events and 
concomitant medications ; 
• Review of potential protocol -defined SAEs;  
• Revie
w of memory aid  to assess treatment compliance; 
• Collection of study product  bottle for drug accountability , if available ; 
• Collection  of a throat swab and stool  specimen (if available),  if consented for future use 
samples.  
 
If the subject  develops signs or symptoms of pneumonia (including fever, increased work of 
breathing, or increased /worsening  cough) or develops a severe solicited event , the child will be 
referred  to his/her  primary  care provider  or local urgent  care center/ED.  Study  staff will assist in 
facilitating  the follow  up appointment.  The study  staff will share all pertinent  information related to 
the study  with the primary  physician.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
34 7.4 Final  Study  Visit  
 
Visit 3: Outcome  Assessment  Visit #2, Day 19-25 
Subjects  will be seen for a follow -up visit on Day 19-25.  Prior  to this visit, study  staff will make  a 
preliminary  assessment  of the clinical response  using  the electronic  health  record  to determine 
whether  any of the following  events  have occurred since the previous  visit. 
• The subject had a medically  attended  visit to an ED, urgent care, or clinic;  
• The subject was hospitalized;  
• The subject received non-study , systemic antibiotic  therapy;  
• The subject underwent drainage  of pleural  fluid, placement  of a chest tube,  or video 
assisted thoraco scopic  surgery.    
At the follow -up visit, study staff will complete the following procedures:  
• Medical history to determine whether medically attended visits, receipt of non- study 
systemic antibiotics , or surgical procedures have occurred;  
• Assessment of  adequate c linical improvement  as indicated by  a parental report of lack of 
rectal , tympanic,  axillary, or oral temperature ≥ 38.3°C  or 100.9 °F for >24 hours, 
normalization of respiratory rate for age (<50 breaths/minute for children <24 months  of 
age and <40 breaths/minute for children 24-71 months of age), and grading of  cough.  
• Physical  assessment to determine vital signs (temperature, pulse, and respiratory rate) 
and physical assessment (general appearance, hydration status, work of breathing, 
presence of skin rash);  
• Review of the subject’s memory aid to assess and record any solicited events and 
concomitant medications;  
• Review of potential protocol -defined SAEs  
• Review of memory aid  assess treatment compliance (if not reviewed at Visit 2);  
• Collection of study product bottle for drug accountability, if not collected at Visit 2 and if available  
• Collection of a throat swab and stool specimen (if available), if consented for future use samples.  
 
If the subject develops signs or symptoms of pneumonia (including fever, increased work of 
breathing, or increased cough) or develops a severe solicited event , the child will be referred to 
his/her primary care provider or local urgent care center/ED. Study staff will assist in facilitating 
the follow  up appointment.  The study staff will share all pertinent  information  related  to the study  
with the primary physician.  
7.5 Early  Termination Visit  
Subjects  who are withdrawn from the study  will be asked to complete an early termination visit. 
Procedures at the early termination visit will be identical to the outcome assessment visits except no throat  swab  or stool  specimen  (if consented to participate  in the collection of future 
use samples ) will be collected.  Unless they expressly state that they wish to have no additional 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
35 follow -up or data collection, subjects who withdraw from the study will receive a follow -up phone 
call approximately one week  after their withdrawal .  Study staff will review the memory aid and 
determine if any follow -up medical care was sought.  
If the subject  presents  with symptoms  such as fever  and/or  elevated respiratory  rate at the Early  
Termination  visit, the study  team  will inform  the subject ’s PCP/pediatrician  and will urge the 
parent(s)  to follow -up with their primary  provider . 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
36 8 STUDY PROCEDURES/EVALUATIONS 
8.1 Clinical Evaluations  
A screening  medical  history  will be obtained by interview  of subject ’s parents/caregivers  during 
the prescreening telephone call and will be confirmed at the time of enrollment.  Parent(s)/  
guardian(s)  will be queried regarding  a history  of significant  medical  disorders  of the head,  eyes,  
ears,  nose,  throat,  mouth,  cardiovascular  system, lungs,  gastrointestinal tract,  liver,  pancreas,  
kidney,  urologic  system, nervous  system, blood,  lymph  nodes,  endocrine  system, 
musculoskeletal system, skin, and genital/reproductive tract.   A history  of any allergies,  cancer,  
immunodeficiency,  or other  chronic  medical  conditions  will be obtained.   At follow -up visits, an 
interim  medical  history  will be obtained by interview  of subjects  noting  any changes  since the 
previous  clinic  visit or contact .  The interim  medical  history  should include an assess ment  for 
new medical  conditions.  
Medication history  (concomitant  medications)  will include a review  of all current  medications  and 
medications  taken within  30 days  prior to signing  the informed consent  form through  the last 
study  visit.  All medications  will be reported  in the eCRF.   Prescription  and over-the-counter  
drugs  will be included as well as herbals,  vitamins  and supplements.  Use of new medication  
shoul
d prompt  evaluation for the presence  of a new diagnosis  of an acute or chronic  medical  
disease or condition.    
At the enrollment  visit, a physical  assessment to assess eligibility will occur , which  will include 
vital signs  (temperature,  pulse and respiratory rate s); hydration status; an assessment of work  
of breathin g; and presence  of skin rash. If indicated based on subject’s  medical  history  or 
physical  assessment , a more complete physical  examination ( conducted by a study  clinician  
licensed to make medical  diagnoses  and listed  as an investigator  on the Form  FDA 1572) may 
occur.  An initial assessment of clinical response will be obtained to include maximum 
temperature in the past 24 hours and an assessment of improved activity and appetite sinc e 
initiating antibiotic therapy.  
An assessment of clinical response will occur at each follow -up visit. The assessment will 
include parental documentation of maximum temperature in the preceding 24 hours; 
normalization of respiratory rate; presence and extent of cough; occurrence of medic ally 
attended visits including visits to the ED, primary care physician, and urgent care; 
hospitalizations; use of non- study systemic antibiotics (parenteral or oral); and occurrence of 
surgical procedures.  Vital signs  (temperature,  pulse and respiratory  rates) will be collected at 
the enrollment  visit and at each  follow -up visit.   
Solicited  event  assessments  will include an assessment of solicited  events  occurring  from the 
time of enrollment  through  the last visit, Visit 3. All subjects  will complete  a subject  memory  aid 
from the time of enrollment  through  Visit 3. Subject  memory  aids will be reviewed with the 
subject ’s parents  for any discrepancies  or missing  data and will be returned to the subject’ s 
parent (s). 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
37 8.2 Laboratory  Evaluations 
8.2.1  Clinical Laboratory  Evaluations  
No clinical laboratory studies will be performed as part of this protocol.  
8.2.2  Special  Assays or Procedures 
N/A 
8.2.3  Specimen Preparation,  Handling,  and Shipping  
N/A 
8.2.3.1  Instructions  for Specimen Preparation,  Handling,  and Storage  
Specific  instructions  will be included in the Manual  of Procedures  (MOP)  
If the subject’s parent/legal guardian consents to future use, clinical site personnel will obtain 
throat swabs and arrange collection of stool samples. Routine throat swabs will be obtained by 
site personnel at the time of enrollment, Outcome Assessment Visit #1, and Outcome Assessment Visit #2. Please refer to the MOP for specific details regarding type of swab. At 
enrollment, parents will be provided with a stool collection kit and instructi ons for sample 
collection. Parents will collect a stool sample within 2 days  after the enrollment visit  and within 2 
days  prior to or 2 days after Outcome Assessment Visit s #1 and #2. Parents will be instructed to 
immediately store the stool sample in thei r home freezer. Parents will be instructed to bring the 
stool samples to the clinical site or sites will arrange pickup (e.g., courier services) at the 
subject’s home. Samples will be transported to the laboratory in a freezer pack; once at the laboratory, samples will be stored at approximately  -20°C, with  temporary  excursions  up to -5˚C 
allowable . The microbial community composition has been shown to remain consistent in fecal 
samples stored at room temperature for up to 24 hours and for up to 14 days at 4°C or -20°C.
9,10 
Moreover, samples are stable for up to 6 months at -80°C.9,10   
Throat  Swab s  
Samples will be stored locally  in an approximately 4˚C refrigerator , with  temporary  excursions 
up to 8˚C allowable,  for up to 48 hours after collection.  Samples will then be held in a -20˚C 
freezer (with temporary excursions to -5˚C allowable) until they are batch shipped to the DMID  
Clinical Materials Services  (CMS ). 
 Stool  Samples  
Stool  specimens  will be obtained at Visits  1, 2, and 3. Specimens  will be collected by retention of 
a fecal  containing diaper  or by collection  of stool  into a sterile  cup that will be provided to the 
subject’s parent/legal guardian. Samples  can be collected within  2 days  of the study  visit and 
maintained in a freezer  in the subject’s  home until sent by courier  or collected by study  staff and 
transported  to the study  site. A minimum  of approximately  2 teaspoons  of stool  will be collected.  
Samples  will be stored locally  and shipped according  to Section 8.2.3.2.  
  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
38 8.2.3.2  Specimen Shipment  
Specific  instructions  will be included in the Manual  of Procedures  (MOP)  
All specimens  will be transported or shipped via courier under controlled conditions to the site (if 
collected at a home visit  or affiliated clinic ) and stored according to the MOP in order to maintain 
appropriate storage temperatures.   When requested, samples  will be batch- shipped to the DMID 
CMS per instructions in the MOP.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
39 9 ASSESSMENT  OF SAFETY  
9.1 Specification  of Safety  Parameters  
Amoxicillin,  amoxicillin -clavulanate,  cefdinir  are approved drugs  with established and well-
described safety  profile.  The most  prevalent  of the drug side effects  include :  
Amoxicillin:  Common side effects include rash, diarrhea, nausea, vomiting, and 
mucocutaneous candidiasis. Rare side effects include: 
• Cardiovascular: hypersensitivity angiitis  
• Central nervous system: agitation, a nxiety, behavioral changes, confusion, dizziness, 
headache, hyperactivity (reversible), insomnia, seizure  
• Dermatologic: acute generalized exanthematous pustulosis , erythema multiforme, 
exfoliative dermatitis, Stevens -Johnson syndrome, toxic epidermal necr olysis, urticaria  
• Gastrointestinal: dental discoloration (brown, yellow, or gray; rare) , hemorrhagic colitis, 
melanoglossia, pseudomembranous colitis  
• Genitourinary: crystalluria  
• Hematologic & oncologic: agranulocytosis, anemia, eosinophilia, hemolytic anemia, 
leukopenia,  thrombocytopenia, thrombocytopeni c purpura  
• Hepatic: cholestatic hepatitis, cholestatic jaundice, hepatitis (acute cytolytic), increased 
hepative enzymes  
• Hypersensitivity: anaphylaxis  
• Immunologic: serum sickness -like reaction  
Amoxicillin -clavulanate  (in addition to side effects listed for amoxicillin above) : Common 
side effects include diaper rash, abdominal discomfort, and loose stools. Other reported side 
effects include:  
• Dermatologic: d iaper rash, urticaria  
• Gastrointestinal: abdominal distress, diarrhea, loose stools, nausea, vomiting  
• Genitourinary: vaginitis  
• Infection: candidiasis, vaginal mycosis  
• Rare but important or life -threatening: cholestatic jaundice, h eadache , hepatotoxicity 
(idiosyncratic), increased liver enzymes, increased serum alkaline phosphatase, 
prolonged prothrombin time, thrombocythemia, vasculitis (hypersensitivity)  
Cefdinir : Common side effects include rash, abdominal pain, nausea, vomiting, diarrhea, 
headache, and mucocutaneous candidiasis.  Other side effects incl ude: 
• Central nervous system: headache 
• Endocrine & metabolic: decreased serum bicarbonate, glycosuria, hyperglycemia, 
hyperphosphatemia, increased gamma -glutamyl transferase, increased lactate 
dehydrogenase  
• Genitourinary: Proteinuria, occult blood in urine, urine alkalinization 
• Hematologic: eosinophilia, lymphocytopenia, lymphocytosis, thrombocythemia, anemia  
• Hepatic: increased serum alkaline phosphatase, increased serum ALT 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
40 • Rare but important or life -threatening: anaphylaxis, anorexia, blood coagulation dis order, 
bloody diarrhea, cholestasis, conjunctivitis, erythema multiforme, erythema nodosum, 
fulminant hepatitis, hemolytic anemia, hepatitis (acute), interstitial pneumonitis (idiopathic), pseudomembranous colitis, r enal failure (acute), and Stevens -Johnson 
syndrome 
As amoxicillin,  amoxicillin -clavulanate,  cefdinir  are approved drugs  with long prescribing history,  
NIAID  does  not expect  that any new drug related safety  signal  will be detected in this trial. As 
such,  the safety  data collection  will be targeted  to only collect  protocol defined SAEs and 
Suspected Unexpected  Serious  Adverse Reaction  (SUSAR, See Section 9.2.2) . 
9.2 Methods  and Timing  for Assessing,  Recording,  and Analyzing Safety  
Parameters  
9.2.1  Adverse Events  
Adverse Event  (AE):  International Conference on Harmonisation (ICH)  E6 defines  an AE as 
any untoward medical  occurrence  in a patient  or clinical investigation  subject  administered  a 
pharmaceutical product  regardless  of its causal  relationship to the study  treatment.  FDA defines  
an AE as any untoward medical  occurrence  associated with the use of a drug in humans,  
whether  or not considered drug related . An AE can therefore  be any unfavorable and 
unintended sign (including an abnormal  laboratory  finding),  symptom,  or disease temporally  
associated with the use of a medicinal  (investigational)  product.  
As the safety  profile  of amoxicillin,  amoxicillin -clavulanate,  and cefdinir  are well established,  and 
this trial is not powered to detect  new,  unknown safety  signals , there will be no unsolicited AE 
collec 
tion during this study and only protocol- defined SAE’s will be collected. 
Solicited adverse events that are common and known to occur following administration of  the 
study product . Solicited adverse events will be recorded daily for the duration of the study  (See 
Table 3) . In addition to the solicited adverse events specified in Table 3, the presence  and 
severity of cough (Table 2) will be recorded daily for the duration of the study to allow for 
assessment of the resolution of pneumonia symptoms.  
9.2.2  Serious Adverse Events 
Serious Adverse Event  (SAE) : An adverse event  or suspected  adverse reaction is considered 
“serious”  if, in the view of either  the investigator  or sponsor,  it results  in any of the following  
outcomes :  
• Death,  
• a life-threatening adverse event1,  
• inpatient  hospitalization or prolongation of existing  hospitalization,   
                                                
 
1 Life-threatening adverse event. An adverse event is considered “life -threatening” if, in the view of either the investigator or sponsor, 
its occurrence places the subject or subject at immediate risk of death.  It does not include an adverse event, had it occurr ed in a 
more severe form, might have caused death.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
41 • a persistent  or significant incapacity  or substantial  disruption  of the ability  to conduct  
normal  life functions ,  
• Important  medical  events  that may not result  in death,  be life-threatening,  or require  
hospitalizations  may be considered serious  when,  based  upon appropriate  medical  
judgment  they may jeopardize the subject  and may require  medical  or surgical  
intervention to prevent  one of the outcomes  listed  in this definition.   Examples  of such 
medical  events  include allergic  bronchospasm  requiring  intensive  treatment  in an 
emergency  room  or at home,  blood dyscrasias  or convulsions  that do not result  in 
inpatient  hospitalization,  or the development  of drug dependency  or drug abuse.  
 
Protocol defined SAEs:  For this protocol , only the following  SAEs will be collected, regardless 
of the relationship to study drug.  
• Death that is not the result of trauma or accident  
• Anaphylaxis  
• Laryngospasm  or bronchospasm  within 1 day after  initiation  of the study treatmen t 
• Stevens -Johnson syndrome  
• Severe erythema multiforme  
• Toxic epidermal necrolysi s 
SAEs must be graded for severity and assessed for relationship to study product (see 
definitions below).   
Severity of Event:   SAEs will be assessed by a licensed study physician listed on the Form 
FDA 1572 as the site principal investigator or appropriate sub- investigator using a protocol -
defined grading system .  For events not included in the protocol -defined grading system, the 
following guid elines will be used to quantify severity:  
• Mild (Grade 1):  Events require minimal or no treatment and do not interfere with the 
subject’s daily activities.  
• Moderate (Grade 2):  Events result in a low level of inconvenience or concern with 
therapeutic measures.  Moderate events may cause some interference with functioning 
and daily activities.  
• Severe (Grade 3):  Events interrupt the subject’s usual daily activities and may require 
systemic drug therapy or other treatment.  Severe events are usually incapacitating.  
Relationship to Study Product:   The study physician’s assessment of an SAE's relationship to 
study product is part of the documentation process, but it is not a factor in determining what is or 
is not reported in this study.  If there is any doubt as to whether a clinical observation is an SAE, 
the event should be reported.  The relationship to study product must be assessed for SAEs 
using the terms: related or not related. In a clinical trial, the study product must always be 
suspect. To help assess, the following guidelines are used:  
• Related – There is a reasonable possibility that the study product caused the adverse 
event.  Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
42 • Not Related – There is not a reasonable possibility that the administration of the study 
product caused the event.  
9.2.3  Procedures to be Followed  in the Event  of Abnormal  Clinical  Findings 
 
Subjects  will be evaluated for the adequacy  of clinical response and for the occurrence  of 
solicited events at the outcome  assessment  visits.   If a serious adverse event is suspected, or if 
clinical response is inadequate, subjects will be referred immediately to their primary provider or 
local ED/urgent care .  
9.3 Reporting  Procedures  
9.3.1  Serious Adverse Events 
All SAEs  will be: 
• Assessed for severity  and causal  relationship by a physician listed  on the Form  FDA 1572 
as the principal  investigator  (PI) or sub-investigator.  
• Recorded on the appropriate SAE report  form.  
• Followed through resolution by a study  physician.  
• Reviewed  by the safety  monitor,  the DSMB  (periodic  review  unless  associated),  DMID  
Medical Monitor , and the local IRB. 
Death,  life-threatening events,  hospitalization or prolongation of existing  hospitalization,  and 
other  important  medical  events  are part of the efficacy endpoints  of this trial and will not be 
reported or collected  as SAEs , unless meeting the SAE reporting criteria included in Section 
9.2.2. 
Any AE that meets a protocol -defined serious criterion must be submitted immediately (within 24 
hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group at the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20814, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897 -1709 (outside US)  
SAE FAX: 1 -800-275 -7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
 
In addition to the SAE form, selected SAE data fields must also be entered into the Emmes  
AdvantageEDC web- based data entry system. Refer to the Manual of Proc edures for details 
regarding this procedure. Timelines for submission of an SAE form are as follows:  
• All non-accidental deaths and life -threatening events, regardless of relationship, will be 
recorded on the SAE form and sent by fax within 24 hours of site awareness of the death 
or event.  
• All other SAEs, regardless of relationship, will be reported via fax by the site within 24 
hours of becoming aware of the event.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
43  
 
Other supporting documentation of the event may be requested by the pharmacovigilance 
contractor and should be provided as soon as possible.  
 All SAEs will be followed until satisfactory resolution or until the PI or sub -investigator deems 
the event to be chronic or the subject to be stable.  
9.3.2  Regulatory  Reporting for Studies Conducted Under  DMID-Sponsored IND 
Following  notification  from the site principal  investigator  or appropriate  sub-investigator , DMID,  
the Investigational  New Drug  (IND)  sponsor,  will report  any suspected adverse reaction that is 
both serious  and unexpected.   DMID  will report  an adverse event  as a suspected adverse  
reaction only if there  is evidence to suggest  a causal  relationship between the drug and the 
adverse event.   DMID  will notify  FDA and all participating  site principal  investigators  (i.e., all 
principal  investigators  to whom  the sponsor  is providing  drug under  its IND(s)  or under  any 
principal  investigator’s  IND(s))  in an IND safety  report  of potential  serious  risks from clinical 
trials  or any other  source,  as soon  as possible,  but in no case later than 15 calendar  days  after 
the sponsor  determines  that the information  qualifies  for reporting  as specified  in 21 CFR Part 
312.32.   DMID  will also notify  FDA of any unexpected fatal or life-threatening suspected adverse  
reaction as soon  as possible,  but in no case later than 7 calendar  days  after the sponsor’s  initial 
receipt  of the information.   Relevant  fo
 llow up information  to an IND safety  report  will be 
submitted as soon  as the information  is available.   Upon request  from FDA,  DMID  will submit  to 
FDA any additional data or information  that the agency  deems  necessary,  as soon as possible,  
but in no case later than 15 calendar  days  after receiving  the request.  
All serious  events  designated as “not related”  to study  product(s),  will be reported  to the FDA at 
least  annually  in a summary  format.  
9.4 Type and Duration  of Follow -up of Subjects after  Adverse Events  
Study  related solicited  events  will be followed until the final study visit .  
9.5 Halting  Rules  
9.5.1  Study Halting Rules  
Subject  safety  data will be reviewed on an ongoing basis.  If any of the following  events  occur 
while  a subject  is on study,  then enrollment  will be stopped  and data will be reviewed.  A 
decision to proceed  or to terminate  the trial will be made  in consultation with the DSMB , 
NIH/NIAID/DMID, and the clinical investigators.   
 
Further study enrollment will be halted for DSMB review/recommendation if any of the following 
are reported:  
• Hospitalization of 2 subjects (or > 2% if more than 100 subjects enrolled)  that requires 
intensive care or leads to death due to persistent/worsening pneumonia  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
44 • More than five subjects (>5% if more than 100 subjects en rolled)  experience 
persistent/worsening pneumonia within 3 days of initiation of study treatment  
o Persistent/worsening pneumonia is a clinical diagnosis, accompanied by the 
following clinical characteristics:  
 administration of non-study directed systemic antibiotic therapy, 
hospitalization, or surgical intervention (e.g., placement of a chest tube) 
for persistent/worsening pneumonia 
• More than 2 subjects (>2% if more than 100 subjects enrolled)  experience an SAE of 
laryngospasm, bronchospasm, or anaphylaxis within 1 day after  initiation  of study 
treatment that is suspected to be related to study product.  
• More than 2 subjects (>2% if more than 100 subjects enr olled)  experience death (that is 
not the result of trauma or accident) within 3 days  of initiation of study treatment and is 
suspected to be related to study product. 
9.5.2  Individual Halting Rules (Termination of Study Product Administration)  
 
Study product administration may be discontinued if any of the following criteria are met: 
• Any clinical adverse event  (AE),  intercurrent  illness,  or other  medical  condition occurs  
that, in the opinion of the investigator, continued receipt of study product would not be in 
the best interest  of the subject ; 
• New onset  of illness  or condition that meets  exclusion criteria  
• Inadequate clinical response that requires off -study antimicrobial therapy.  
o Subjects who require off -study antimicrobial therapy will be defined as having an 
inadequate clinical response.  
Subjects may stop study drug treatment at any time of their own volition or at the advice of their 
treating provider or the study investigators.  Subjects who stop study product for any reason will be regarded as having withdrawn from treatment but not as having withdrawn from the study 
(i.e, s ubjects will be asked to continue to participate in follow -up visits ). All subjects  with an 
inadequate clinical response will be referred to a non-study healthcare provider for evaluation 
and possible treatment outside of the clinical study.  
 At the time of withdrawal, subjects will undergo an early termination visit if they are not willing to 
participate in the remaining follow -up visits  
9.6 Safet y Oversight 
9.6.1  
Data and Safety Monitorin g Board (DSMB)  
Safety oversight will be conducted by a DSMB that is an independent group of experts that 
monitors subject safety and advises DMID. The DSMB members will be separate and 
independent of study personnel participating in this trial and should not have scientific, financial 
or other conflict of interest related to the study. The DSMB will consist of members with 
appropriate expertise to contribute to the interpretation of the data from this trial.  
The DSMB wil l review study progress and participant, clinical and safety data at the following 
time points:  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
45 • Annually at the completion of each respiratory disease season;  
• Final review meeting,  approximately 6-8 months  after clinical database lock to review the 
cumulative unblinded safety and efficacy data for this trial.   The data will be provided in a 
standard summary format ; 
• Ad hoc when a halting rule is met, for immediate concerns regarding observations during 
the study, or  as needed.  
The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. At this time, each data element that the DSMB needs to 
assess will be clearly defined. Procedures for DSMB reviews/meetings will be defined in the 
charter. The DSMB will review applicable data to include, but not limited to, study progress and 
participant, clinical, and safety data that may include enrollment and demographic information , 
medical history, concomitant medications, physical assessments, dosing, solicited events, and 
SAEs. Additional data may be requested by the DSMB, and interim statistical reports may be 
generated as deemed necessary and appropriate by DMID. The DSMB may receive data in 
aggregate and presented by group. The DSMB will meet and review this data at scheduled time 
points or ad hoc as needed during the study as defined in the DSMB charter. As an outcome of 
each review/meeting, the DSMB will make a recommendation as to the advisability of proceeding with st udy product administration, and to continue, modify, or terminate the study.  
DMID , the PI, or the DSMB chair may convene the DSMB on an ad hoc basis according to 
protocol criteria or if there are immediate concerns regarding observations during the course of 
the study. The DMID Medical Monitor is empowered to stop enrollment and study treatment if the halting criteria is met or in case of any safety concern. The DMID Medical Monitor will be 
responsible for reviewing SAEs in real time. The DSMB will review SAEs on a regular basis and 
ad hoc during the study.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
46 10 CLINICAL MONITORING  
10.1 Site Monitoring Plan  
Site monitoring  is conducted to ensure  that the human subject  protections,  study  and laboratory  
procedures,  study  intervention administration,  and data collection  processes  are of high quality  
and meet  sponsor,  ICH/GCP  guidelines  and applicable regulations , and that the study  is 
conducted in accordance  with the protocol,  protocol -specific  MOP  and applicable sponsor  
standard  operating procedures.   DMID,  the sponsoring agency,  or its designee will conduct  site-
monitoring visits  as detailed in the clinical monitoring  plan.  
Site visits  will be made at standard  intervals  as defined  by DMID  in a separate monitoring plan 
and may be made  more  frequently  as directed  by DMID.   Monitoring visits  will include,  but are 
not limited  to, review  of regulatory  files, accountability  records,  eCRFs,  informed  consent  forms,  
medical  and laboratory  reports,  and protocol  and GCP  compliance.   Site monitors  will have  
access to the stu dy site, study  personnel,  and all study  documentation  according to the DMID -
approved site monitoring plan.   Study  monitors  will meet  with site principal  investigators  to 
discuss any issues noted  
 
In this protocol, a ‘specific site’ is defined as one in which resources for the study (e.g., study staff, storage facilities, drug storage, or study records) are housed.  Monitoring visits will focus 
on these specific sites to ensure compliance with DMID and ICH/GCP policies, procedures, and 
guidelines. In addition, a significant number of visits will occur in non -site locations, such as 
community clinics or home visits. These ‘generic’ sites will not be considered part of the site 
monitoring plan.  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
47 11 STATIS TICAL  CONSIDERATIONS 
This is a randomized double- blinded placebo- controlled trial comparing  a strategy  of short  course 
(5-days)  vs. standard course (10-days)  oral beta-lactam  antibiotic  therapy  with respect  to 
desirability  of outcome in children with CAP.   
The trial is designed  using Response  Adjusted  for Days  of Antibiotic  Risk (RADAR).11 RADAR 
utilizes  a superiority  trial design  under  the conceptual  framework,  evaluating whether  a strategy  
of short  course  antibiotic  therapy  is better  than the standard course strategy  when considering 
the totality  of all of the important  outcomes  (adequacy  of the clinical response,  adverse  events,  
and the duration of antibiotic  use).   
All trial participants  are assigned a desirability  of outcome  ranking  (DOOR),  constructed as 
follows:   
I. Each  subject  is evaluated according  to the ordinal  clinical response ( Refer  to Section  
3.2.1 ) 
II. DOOR  is assigned according  to two rules:  
(i) When  comparing  two subject s with different  ordinal  clinical responses , the subject  
with a better  ordinal  clinical response  receives  a higher  rank.  
(ii) When comparing two subjects with the same ordinal clinical response, the subject 
with fewer days of antibiotic use receives a higher rank. Days of antibiotic use are 
defined as the number of days for which the subject is reported to have taken at least one dose of non- placebo study product or a non- study product systemic 
antibiotic.  
During  analyses,  the distributions  of DOORs  are compared  between short -course  and standard -
course  strategies.  The s
 um of the probability  that a randomly  selected participant  from the short  
course strategy  will have  a better  DOOR  than a randomly  selected participant  from the standard  
course  strategy  plus one- half the probability that the DOORs are equal  is estimated using  a 
confidence interval.   
The primary  outcome  measure is the DOOR  at Outcome Assessment Visit #1 (defined above).  
DOOR at Outcome Assessment Visit #1 is computed using data from Day 1 to Day 5.  
Secondary outcome measures include:  
1. DOOR at Outcome Assessment Visit #2.  
2. Resolution of symptoms (a component of DOOR) at each outcome assessment visit, defined as the absence of fever, tachypnea, or cough of grade 2 or higher.  
3. Adequate clinical response rates (a component of DOOR) at each outcome assessment visit, defined as the absence of a medically attended visit to an ED or outpatient clinic or hospitalization for persistent or worsening pneumonia that occurs after randomization and 
receipt of at least one dose of study drug.  
4. Frequency of solicited events at each outcome assessment visit, as listed in Table 3.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
48 5. Medically  attended visits  to ED or clinic ; hospitalizations ; surgical  procedures ; and receipt  
of non-study  systemic antibiotics  for persistent or worsening pneumonia  (as defined 
above) at each outcome assessment visit  
i. Individual event types (e.g., medical visits , hospitalizations , surgical procedures , 
and receipt of non -study systemic antibiotics) will be compared between treatment 
groups.  
6. Medically attended visits to ED or clinic; hospitalizations; surgical procedures; and receipt 
of non -study systemic antibiotics  for all causes  at each outcome assessment visit   
i. Individual event types (e.g., medical visits , hospitalizations surgical procedures , and 
receipt of non -study systemic antibiotic ) will be compared between treatment 
groups.  
Exploratory  outcome  measures incl ude: 
1. DOOR at Outcome Assessment Visits #1 and #2, when increasing the threshold in 
assigning different ranks due to differing numbers of days of antibiotic use from a one 
day difference to a two, three, four, or five day difference.   
11.1 Study Hypothesis 
• N ull: the sum of the probability that a subject assigned to the 5- day arm will have 
a higher DOOR than if assigned to the 10- day arm plus one- half the probability of 
equal DOORs is 50% (i.e., no difference in DOOR).   
11.2 Sample Size Considerations  
The primary study  sample size is based on a superiority test of the null hypothesis in 11.1, 
under an assumed alternative hypothesis that the sum of the probability  that a subject assigned 
to the 5- day arm  will have a higher  DOOR  than if assigned  to the 10-day arm plus one -half the 
probability of equal DOORs  is 60%  (p=60%) .  
A sample size of 360 (180 per arm) provides  90% power  using a 2- sided alpha=0.05  with a 
Wilcoxon Mann- Whitney  U test. If p=65%  or 70%,  then a total sample  size of 160 (80 per arm) 
or 90 (45 per arm),  respectively,  would be required.   The sample  size is inflated  by ~10%  based  
on an estimate  from a similar  study,  in order  to account  for loss to follow -up resulting  in a total 
sample size of 400 (200/arm).   
11.3 Planned Interim  Analyses  
11.3.1  Safety  Review   
A Data Safety Monitoring Board (DSMB) appointed by NIAID will monitor this protocol.  Interim 
safety review may include enrollment and demographic information, medical history, concomitant 
medications, physical assessments, dosing, and protocol specific  SAEs  and SUSAR . Additional 
data may be requested by the DSMB, and interim statistical reports may be generated as deemed necessary and appropriate by DMID. The DSMB may receive data in aggregate and presented 
by treatment group. The DSMB will meet and review  this data at scheduled time points or ad hoc 
as needed during the study as defined in the DSMB charter. As an outcome of each 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
49 review/meeting, the DSMB will make a recommendation as to the advisability of proceeding with 
the study or to modify or terminate the study.  
Additionally, the study will be monitored to determine if any of the halting rules described in Section 9.5 are met.  
11.3.1  
Interim Analysis of Efficacy, Futility, and Safety  
One interim analysis, described below, will be performed and reported to the DSMB after at least  
30% of the targeted subjects have completed the study.  The interim analysis will inform DSMB 
decisions regarding stopping early for efficacy, futility, or safety.  
For the interim analysis, a snapshot of the study database will be unblinded and used to conduct  analyses as follows.  An ITT analysis including all enrolled subjects in the snapshot of 
the study database will be performed, testing the null hypothesis provided in Section 11.1 using the methods described in Section 11.4.1, with the modification that the Haybittle- Peto boundary 
(p<0.001) will be used when concluding statistical significance.  The study may be stopped early for efficacy only if statistical significance is detected in that test.  In the event of statistical 
significance, sensitivity analyses using complete case and according -to-protocol cohorts (CC -V1 
and ATP -V1, as described below) as well as worst case analyses will be included in the DSMB 
report to further guide decisions for stopping for efficacy.   
A 95% con fidence interval for the probability that a randomly selected subject will have a better 
DOOR if assigned to the 5- day strategy (vs. the standard strategy) will be estimated but not 
used to inform DSMB decisions about stopping early for efficacy. Predicted interval plots 
(PIPS)
12,13 will be constructed to provide the DSMB with a prediction of the trial results were the 
trial to continue as planned under varying assumptions regarding future data (e.g., current trend continues, null hypothesis is true, alternative hypothesis is true).  
The DSMB  will also be provided with the following: 
1. For subjects that have completed Outcome Assessment Visit #1  and have received at least 
one dose of study product, a between arm difference in the overall outcome (DOOR) via a 
cumulative difference plot with respective confidence bands for Outcome Assessment Visit #1 
2. For subjects that have completed Outcome Assessment Visit #1  and have received at least 
one dose of study product, a forest plot of 95% confidence intervals for the risk difference of 
adequate clinical response as well as the following interventions for persistent or worsening 
pneumonia:  (1) ED/clinic visits, (2) hospitalizations, (3) surgical procedures, and (4) non-
study systemic antibiotics at Outcome Assessment Visit #1.  
3. For subjects that have completed Outcome Assessment Visit #1  and have received at least 
one dose of study product, a forest plot of 95% confidence intervals for the risk difference of 
lack of resolution of symptoms as well as the following: (1) Oral, rectal, axillary or tympanic 
temperature ≥38.3˚C (100.9˚F), confirmed by repeat measurement after at least 15 minutes, 
in the 24 hours  preceding Outcome Assessment Visit  #1, unless attributed to a new process 
that is unrelated to the prior diagnosis of pneumonia;  (2) Elevated respiratory rate  (RR >50 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
50 breaths/minute for children <24 months of age and >40 breaths/minute for children 24- 71 
months of age) at Outcome Assessment Visit  #1, and (3) Presence of cough Grade 2 or 3 at 
Outcome Assessment Visit  #1. 
4. For subjects that have completed Outcome Assessment Visit #1  and have received at least 
one dose of study product, a forest plot of 95% confidence intervals for the risk difference of 
each solicited event and with the risk difference of any solicited event, for each severity 
threshold (mild or greater, moderate or greater, or severe) for Outcome Assessment Visit 
#1. 
11.4 Final  Analysis Plan  
The primary analysis of the primary endpoint will be performed according to an intention- to-treat 
(ITT) approach and include all randomized subjects.  As (secondary) sensitivity analyses of the 
primary endpoint, complete case analyses using the CC -V1 / ATP -V1 cohorts (defined below) 
and a worst case analysis using the ITT cohort of the primary endpoint will be performed.  
Additional analyses may be performed and are described in detail in the Statistical Analysis 
Plan.  
Intention- to-Treat Cohort: All randomized participants, analyzed as randomized.   Subjects that 
have not received at least one dose of study product will have adequate clinical response and its sub -components treated as missing.  
Complete Case Cohorts (CC): Subjects in a CC analysis are analyzed as randomized, but excluded from analysis if missing data prevents assigning an unambiguous value to the DOOR 
endpoint  or if the subject has not received at least one dose of study product .  The CC -V1 
cohort will consist of all subjects with sufficient data to define unambiguously the Visit #1 DOOR.  The CC -V2 cohort  will consist of all subjects with sufficient data to define 
unambiguously the Visit #2 DOOR.   
According- to-Protocol Cohorts (ATP): Subjects in an ATP analysis require at least one dose of 
study product each day from Day 1 to Day 5 and furthermore subjects will excluded from 
analysis if missing data prevents assigning an unambiguous value to the DOOR endpoint  The 
ATP- V1 cohort will restrict subjects to those with sufficient data to define unambiguously the 
Visit #1 DOOR.  The ATP -V2 cohort will restrict subjects to those with sufficient data to define 
unambiguously the Visit #2 DOOR.   
Details of what constitutes sufficient data to assign an unambiguous value to DOOR will be 
specified in the statistical analysis plan.  
11.4.1  Primary Analysis 
For the primary analyses, the DOORs will be compared between the 5 - and 10- day arms. The 
sum of the probability that a randomly selected subject will have a better DOOR if assigned to 
the 5 -day arm for Outcome Assessment Visit #1 plus one- half the probabil ity of equal DOORs 
for Outcome Assessment Visit #1 will be estimated. The null hypothesis to be tested is that the probability is equal to 0.50 (lack of superiority of short -course therapy).  The primary analysis 
will be carried out using the ITT cohort, with missing DOOR values (treated as continuous) 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
51 imputed using multiple imputation, utilizing linear regression models corresponding to relevant 
observed data (baseline covariates and observed DOOR components from an early termination 
visit, if available). The Mann- Whitney U statistic will be combined across the datasets to give the 
test statistic and Rubin’s Rules used to define distribution of the test statistic under the  null hypothesis.  The test of the null hypothesis will be two- sided with a Type I error of 0.05.  A point 
estimate of the estimand will be computed by dividing combined test statistic by the number of 
pairwise comparisons and a confidence interval of the estimand will be computed by inverting 
the described test of the null hypothesis.  
Note: Subjects will be asked to confirm fever with repeat testing after approximately 15 minutes; 
for analysis purposes, subjects lacking a repeat measurement will be considered as having 
developed fever.  
11.4.2  Secondary Analyses  
All secondary and exploratory analyses will use a Type I error rate of 0.05 and will not correct for multiple comparisons.  All tests will be two- sided.  
Secondary analyses will include:  
• Analysis of  DOOR at Outcome Assessment Visit #2, performed as ITT in an analogous 
manner to the primary analysis . 
• Sensitivity Analyses for the DOOR at Outcome Assessment Visits #1 and #2 ITT analyses.  (1) CC analyses.  (2) ATP analyses.  (3) Worst case analyses: all imputations of missing data will be the worst case (result in the lowest possible DOOR given available information) for subjects in the 5 -day arm and best case for subjects in the 10-
day arm.  Sensitivity analyses will test the null hypothesis using the Mann- Whitney U 
Test, estimate using U divided by the number of pairwise comparisons, and will compute 
confidence intervals by (1) inverting the Mann- Whitney U Test and (2) using a non -
parametric bootstrap.  
• Separately for Outcome Assessment Visit #1 and #2, using CC cohorts, a forest plot of 95% confidence intervals for the risk difference of each s olicited event and the risk 
difference  of any solicited, for each severity threshold (mild or greater, moderate or 
greater, or severe).  Tests for differences in proportions between treatment arms will be given by Fisher’s exact tests.  
• Separately for Outco me Assessment Visit #1 and #2, using CC cohorts, a forest plot of 
95% confidence intervals for the risk difference of lack of resolution of symptoms as well 
as the following: (1) Oral, rectal, axillary or tympanic temperature ≥38.3˚C (100.9˚F), 
confirmed b y repeat measurement after at least 15 minutes, in the 24 hours preceding 
the Outcome Assessment Visit, unless attributed to a new process that is unrelated to 
the prior diagnosis of pneumonia;  (2) Elevated respiratory rate (RR >50 breaths/minute 
for child ren <24 months of age and >40 breaths/minute for children 24 -71 months of 
age) at the time of the Outcome Assessment Visit;  and (3) Presence of cough Grade 2 
or 3 at the Outcome Assessment Visit.  Tests for differences in proportions between treatment arms  will be given by Fisher’s exact tests.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
52 • Separately for Outcome Assessment Visit #1 and #2, using CC cohorts, a forest plot of 
95% confidence intervals for the risk difference of adequate clinical response as well as 
the following interventions for persistent or worsening pneumonia:  (1) ED/clinic visits, (2) 
hospitalizations, (3) surgical procedures, and (4) non- study systemic antibiotics.  Tests 
for differences in proportions between treatment arms will be given by Fisher’s exact tests.  
• Separately f or Outcome Assessment Visit #1 and #2, using CC cohorts, a forest plot of 
95% confidence intervals for the risk difference of adequate clinical response as well as 
the following interventions for all causes:  (1) ED/clinic visits, (2) hospitalizations, (3) 
surgical procedures, and (4) non -study systemic antibiotics.  Tests for differences in 
proportions between treatment arms will be given by Fisher’s exact tests. 
• Analysis of the ordinal clinical response at Outcome Assessment Visits #1 and #2.  The ITT analysis will treat the ordinal clinical response as Normal distributed and use multiple 
imputation to compute confidence intervals for the mean ordinal clinical response by 
treatment assignment and to test whether the mean ordinal clinical response varies by 
treatment assignment.  CC, ATP, and worst case analyses of the ordinal clinical 
response will be performed; separately for Outcome Assessment Visit #1 and #2, a cumulative difference plot with respective 95% confidence bands for the ordinal clinical 
response (and an associated result from a Mantel -Hantzel chi -square test on the ordinal 
clinical response) will be computed.  Non-inferiority analyses of the ordinal clinical 
response at Outcome Assessment Visits #1 and #2 using the ITT cohort, to be specified 
in the statistical analysis plan, may be carried out.  
11.4.3  Exploratory Analyses  
Increased RADAR thresholds sensitivity analysis.  In the primary RADAR/DOOR analysis, if two subjects from separate treatment arms have an equal ordinal clinical response but a differ ence 
in the duration of antibiotic use of at least 𝑘𝑘= 1  day, RADAR assigns a more favorable 
response to the subject with fewer days of antibiotic use.  For a sensitivity analysis, the effect of 
increasing the minimum difference in the duration of antibiot ic use (𝑘𝑘= 2,3,4, or 5) before a 
favorable response is given to the subject with shorter duration of antibiotic use will be explored.  
For each value of 𝑘𝑘, bootstrapped confidence intervals of the probability of more favorable 
DOOR due to assignment to the 5 -day antibiotic course will be computed and plotted versus 𝑘𝑘.  
Analysis will be performed separately for DOOR at Outcome Assessment Visit #1 and DOOR at Outcome Assessment Visit #2.   Analyses will be performed using CC -V1/CC -V2 cohorts.  
Other exploratory analyses, if required,  to be specified in the statistical analysis plan.  
  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
53 12 SOURCE DOCUMENTS AND  ACCESS TO  SOURCE  
DATA/DOCUMENTS 
Each  participating site will maintain appropriate  medical  and research records  for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory  and institutional  requirements  for the 
protection of confidentiality  of subjects.   Each  site will permit  authorized representatives  of the 
DMID,  its designees,  and appropriate regulatory  agencies  to examine (and when required by 
applicable law, to copy)  clinical records  for the purposes  of quality  assurance reviews,  audits,  
and evaluation of the study  safety  and progress.   These  representatives  will be permitted  
access to all source data,  which  include,  but are not limited  to, hospital  records,  clinical and 
office  charts,  laboratory  notes,  memoranda,  subjects’ memory  aid or evaluation checklists,  
pharmacy  dispensing  records,  recorded data from automated  instruments,  copies  or 
transcriptions  certified after verification as being  accurate  and complete,  microfiches, 
photographic  negatives,  microfilm  or magnetic  media,  x-rays,  and subject  files and records  kept 
at the pharmacy,  at the laboratories,  and medico- technical  departments  involved in the clinical 
trial.  Data  collection  forms  will be derived from the eCRFs  and be provided by the Statistical  
and Data  Coordinating  Center  (SDCC). 
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
54 13 QUALITY  CONTROL AND  QUALITY  ASSURANCE  
Following  a written  DMID -accepted  site quality  management  plan,  the participating VTEU  sites 
and its subcontractors are responsible for conducting routine quality  assurance (QA) and quality  
control  (QC)  activities  to internally  monitor  study  progress  and protocol  compliance.   The site 
principal  investigator  will provide direct  access  to all trial-related  sites,  source data/data  
collection  forms,  and reports  for the purpose  of monitoring and auditing by the sponsor,  and 
inspection by local and regulatory  authorities.   The site principal  investigator  will ensure all study  
personnel  are appropriately  trained and applicable documentations  are maintained on site. 
The SDCC will implement  quality  control  procedures  beginning with the data entry  system and 
generate  data quality  control  checks  that will be run on the database.   Any missing  data or data 
anomalies  will be communicated to the site(s)  for clarification  and resolution.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
55 14 ETHICS/PROTECTION OF HUMAN  SUBJECTS 
14.1 Ethical  Standard  
The site principal  investigator  will ensure that this trial is conducted in full conformity  with 
principles  of the Belmont  Report:   Ethical  Principles  and Guidelines  for the Protection of Human  
Subjects  of Research of the National  Commission  for the Protection of Human  Subjects  of 
Biomedical  and Behavioral  Research (April  18, 1979)  and codified in 45 CFR 46, 21 CFR 50 
and 56, and ICH E6; 62 Federal  Regulations  25691 (1997),  if applicable.   The site principal  
investigator’s  Institution  will hold a current  Federal  Wide  Assurance (FWA)  issued by the Office  
of Human  Research Protection (OHRP)  for federally  funded research.  
14.2 Institutional  Review  Board  
Prior  to enrollment  of subjects  into this trial, the approved protocol  and informed  consent  form 
will be reviewed and approved by the appropriate  IRB listed  on its FWA.  
The responsible official for the IRB will sign the IRB letter  of approval  of the protocol  prior to the 
start of this trial and a copy  will be provided to DMID.   The IRB Federal  Wide  Assurance number  
will be provided to DMID.  
Should amendments  to the protocol  be required,  the amendments  will  be written  by the sponsor  
and provided to the site principal  investigator  for submission to the IRB. 
14.3 Informed Consent  Process 
14.3.1  Informed Consent  
The site principal  investigator  will choose subjects  in accordance with the eligibility  criteria  
detailed in Section 5.  Before any study  procedures  are performed,  subjects  must  sign an 
informed  consent  form that complies  with the requirements  of 21 CFR Part 50 and 45 CFR 46 
and the local IRB. 
Informed consent  is a process  that is initiated  prior to an individual  agreeing to participate in a 
trial and continuing throughout  the individual’s  trial participation.   Before any study  procedures  
are performed,  subjects  will receive a comprehensive explanation of the proposed study  
procedures  and study  interventions/products,  including  the nature  and risks of the trial, alternate  
therapies,  any known AEs,  the investigational  status  of the components,  and the other  elements  
that are part of obtaining proper  informed consent.   Subjects  will also receive a detailed 
explanation of the proposed use and disclosure  of their protected  health information.   Subjects  
will be allowed  sufficient  time to consider  participation  in the trial, after having the nature and 
risks of the trial explained to them,  and have the opportunity  to discuss the trial with their f amily,  
friends  or legally  authorized representative or think  about  it prior to agreeing  to participate.  
Informed consent  forms  describing in detail  the study  interventions/products,  study  procedures,  
risks and possible benefits  are given to subjects.   The informed consent  form must  not include 
any exculpatory  statements.   Informed  consent  forms  will be IRB-approved and subjects  will be 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
56 asked  to read and review  the appropriate document.   Upon  reviewing  the appropriate  document,  
the site principal  investigator  (or designee)  will explain  the research  study  to subjects  and 
answer  any questions  that may arise.   Subjects  must  sign the informed consent  form,  and 
written  documentation  of the informed consent  process  is required  prior to starting  any study  
procedures/interventions  being done specifically  for the trial, including  administering  study  
product.  
DMID  will provide the site principal  investigator,  in writing,  any new information that significantly  
impacts  the subjects'  risk of receiving  the investigational  product.   This new information will be 
communicated by the site principal  investigator  to subjects  who consent  to participate in the trial 
in accordance  with IRB requirements.   The informed  consent  document  will be updated  and 
subjects  will be re-consented per IRB requirements,  if necessary.  
Local IRB requirements will govern subject recruitment efforts and pre -enrollment activities.  
Subjects will be given a copy of all informed consent forms that they sign.  By signing  the 
informed  consent  form,  subjects  agree to complete all evaluations  required  by the trial, unless  
the subject  withdraws  voluntarily,  or is withdrawn or terminated from the trial for any reason.  
The rights  and welfare  of subjects  will be protected  by emphasizing  to subjects  that the quality  
of their medical  care will not be adver sely affected  if they decline to participate in or withdraw  
from this trial. 
14.3.2  Informed Consent/Assent  Process  (in Case  of a Minor)  
Parents or legal guardians will be asked to provide consent for the participation of their children 
as outlined in Section 14.3.1. Since all eligible  children in this study are <7 years of age, formal 
written assent will not be obtained; nevertheless, study personnel will explain the study to the child in age appropriate terms and will ensure that the well being of participating children is protected.  
14.4 Exclusion of Women,  Minorities,  and Children (Special  Populations)  
This study  is focused  on children age 6-71 months  of age and will include all racial , ethnic  , and 
gender/sex categories . 
14.5 Subject  Confidentiality  
Subjects  will have  code numbers  and will not be identified by name.  Subject  confidentiality  is 
strictly  held in trust by the participating investigators,  their staff,  and the sponsor(s)  and their 
agents.   
The study  protocol,  documentation,  data,  and all other  information  generated will be held in 
strict confidence.   No information  concerning the study  or the data will be released to any 
unauthorized third party  without  prior written  approval  of the sponsor.  
All information  provided by the Sponsor  and all data and information  generated  by the 
participating  site as part of the trial (other  than a subject’s  medical  records)  will be kept 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
57 confidential  by the site principal  investigator  and other  study  personnel to the extent  permitted  
by law. This information  and data will not be used  by the site principal  investigator  or other  study  
personnel  for any purpose other  than conducting  the trial. These  restrictions  do not apply  to: (1) 
information  which  becomes  publicly  available  through  no fault of the site principal  investigator  or 
other  study  personnel;  (2) information  which  is necessary  to disclose in confidence to an IRB 
solely  for the evaluation of the trial (3) information  which  is necessary  to disclose in order  to 
provide appropriate  medical  care to a study  subject;  or (4) study  results  which  may be published 
as described in Section  16. If a written  contract  for the conduct  of the trial which  includes  
confidentiality  provisions  inconsistent  with this statement  is executed,  that contract’s  
confidentiality  provisions  shall apply  rather  than this statement.  
The study  monitor , applicable regulatory authorities, such as the FDA,  or other  authorized 
representatives  of the sponsor  may inspect  all documents  and records  required to be 
maintained by the investigator,  including but not limited  to, medical  records  (office,  clinic,  or 
hospital)  and pharmacy  records  for the subjects  in this study.   The clinical study  site will permit  
access to such records.  
14.6 Future Use of Stored Specimens  
Subjects will be asked for permission to keep any samples for use in future research studies, 
such as analyzing the impact of antibiotic usage of the microbiome. Some samples may be 
stored at the local site and some at a central clinical storage facility. Samples may be shared with other investigators at other institutions, provided that appropriate human subject protection 
plans are in place.  The samples will not be sold or used directly for production of any 
commercial product. No human genetic tests will be performed on samples. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject’s 
confidentiality.  
There are no benefits to subjects in the collection, storage and subsequent research use of specimens. Reports about future research done with subject’s samples will not be kept in their 
health records.  
Subjects may be given the option to decide if they want their samples to be used for future research or have their samples destroyed at the end of the trial. The subject’s decision can be 
changed at any time prior to the end of the trial by notifying the study doctors or nurses in 
writing. However, if the subject originally consents to future use and subsequently changes 
his/her decision, any data from a previously collected sample may still be used for this research.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
58 15 DATA HANDLING  AND  RECORD  KEEPING  
The investigator  is responsible to ensure the accuracy, completeness , legibility,  and timeliness  
of the data reported.    
Data  collection  forms  will be derived from the eCRFs  and provided by the SDCC to the sites to 
record  and maintain data for each  subject  enrolled in the study.   All source  documents  should 
be completed in a neat,  legible  manner  to ensure  accurate  interpretation of data.   Permanent  ink 
is required  to ensure  clarity  of reproduced  copies.   When  making  a change  or correction,  the 
original  entry  should be crossed out with a single  line, and the change should be initialed  and 
dated.   Do not erase,  overwrite,  or use correction fluid or tape on the original.   
Data  reported  in the eCRF  should be consistent  with the data collection  form/source  documents  
or the discrepancies  should be documented.    
The sponsor  and/or  its designee will provide guidance to investigators  on making  corrections  to 
the data collection  forms  and eCRFs.    
15.1 Data  Management  Responsibilities  
All source documents  and laboratory  reports  must  be reviewed by the clinical team  and data 
entry  staff,  who will ensure that they are accurate  and complete.   A dverse events  must  be 
graded,  assessed for severity  and causality,  and reviewed by the site PI or designee.  
Data  collection  is the responsibility  of the clinical trial staff at the site under  the supervis ion of 
the site PI.  During  the study,  the investigator  must  maintain complete  and accurate  
documentation for the study.  
Emmes  will serve  as the Statistical  and Data  Coordinating  Center  for this study  and will be 
responsible for data management,  quality  review,  analysis,  and reporting  of the study  data.  
15.2 Data  Capture  Methods  
Clinical data (including  solicited  events  and concomitant  medications)  and clinical laboratory  
data will be entered  into a 21 CFR Part 11-compliant  Internet  Data  Entry  System  (IDES)  
provided by Emmes .  The data system includes  password protection and internal  quality  
checks,  such as automatic  range  checks,  to identify  data that appear  inconsistent,  incomplete,  
or inaccurate.   Clinical data will be entered directly  from the source documents.   
15.3 Types of Data  
Data for this study will include clinical, safety, and outcome measures . 
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
59 15.4 Timing/Reports  
A final report will be prepared following the availability of all the safety  and efficacy data. Interim 
statistical reports may be generated as deemed necessary and appropriate by DMID.  Safety 
and efficacy summary reports may be generated for the DSMB.  
After full analysis and final reporting is complete, and upon request and DMID approval, the 
SDCC will provide the participating sites with a summary of results by treatment group and/or subject  treatment assignments.  In this regard, the participating sites requesting such information 
to share with study subjects must do so in compliance with their respective IRB guidelines. 
15.5 Study  Records Retent ion 
Records  and documents  pertaining to the conduct  of this study,  including  data collection  forms,  
source documents,  consent  forms,  laboratory  test results,  and medication inventory  records  
shall be retained for 2 years after a marketing application is approved for the drug; or, if an 
application is not approved for the drug, until 2 years after shipment and delivery of the drug for 
investigational use is discontinued and FDA has been so notified. The site must contact DMID 
for authorization prior to the destruction of any study records. Informed consent forms for future 
use will be maintained as long as the sample exists.  
15.6 Protocol Deviations  
A protocol  deviation is any noncompliance with the clinical trial protocol,  Good Clinical Practice 
(GCP),  or Manual  of Procedures  requirements.   The noncompliance may be either  on the part of 
the subject,  the investigator,  or the study  site staff.  As a result  of deviations,  corrective  actions  
are to be developed by the site and implemented  promptly.   
These  practices  are consistent  with ICH E6: 
4.5 Compliance with Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
5.1 Quality  Assurance  and Quality  Control,  section 5.1.1 
5.20 Noncompliance,  sections  5.20.1,  and 5.20.2.  
It is the responsibility  of the site to use continuous  vigilance  to identify  and report  deviations  
within  5 working  days  of identification of the protocol  deviation,  or within  5 working days  of the 
scheduled protocol -required activity.   All deviations  must  be promptly  reported to DMID,  via the 
Emmes  IDES   
All deviations  fr
 om the protocol  must  be addressed in study  subject  source documents.   A 
completed  copy  of the DMID  Protocol  Deviation  Form  (IDES  form)  must  be maintained  in the 
regulatory  file, as well as in the subject’s  source document.   Protocol  deviations  must  be sent to 
the local IRB/IEC  per their guidelines.   The site PI/study  staff is responsible for knowing  and 
adhering to their IRB/IEC  requirements.  
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
60 16 PUBLICATION POLICY 
Following  completion of the study,  the investigator  is expected to publish the results  of this 
research  in a scientific  journal.   The International  Committee of Medical  Journal  Editors  (ICMJE)  
member  journals  have adopted a trials -registration  policy  as a condition  for publication.  This 
policy  requires  that all clinical trials  be registered  in a public  trials  registry  such  as 
ClinicalTrials.gov *, which  is sponsored by the National  Library  of Medicine.   Other  biomedical  
journals  are considering  adopting similar  policies.   It is the responsibility  of DMID  to register  this 
trial in an acceptable  registry.  Any clinical trial starting  enrollment  after 01 July 2005 must  be 
registered  on or before  subject  enrollment.   For trials  that began  enrollment  prior to this date,  
the ICMJE  member  journals  will require  registration  by 13 September  2005,  before  considering  
the results  of the trial for publication.  
 
The ICMJE  defines  a clinical trial as any research project  that prospectively  assigns  human 
subjects  to intervention or comparison  groups  to study  the cause- and-effect relationship 
between a medical  intervention and a health  outcome.   Studies  designed for other  purposes,  
such as to study  pharmacokinetics  or major  toxicity  (e.g.,  Phase I t rials),  would be exempt  from 
this policy.  
 
DMID Protocol #14- 0079  Version 4.0  
SCOUT -CAP  14 December 2018  
 ____________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
61 17 LITERATURE  REFERENCES  
 
1 Rudan, I., Bosch- Pinto, C. & Biloglav, Z. Epidemiology and etiology of childhood pneumonia. Bull 
World Health Organ  86, 408 (2008).  
2 Kronman, M., Hersh, A. & Feng, R. Ambulatory visit rates and antibiotic prescribing for children 
with pneumonia. Pediatric s 127, 411- 418 (2011).  
3 CDC. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine - United States, 1997- 2006. Morbidity and Mortality Weekly 
Report , 3 (2009).  
4 Jain, S.  et al.  Community -acquired pneumonia requiring hospitalization among U.S. children. N 
Engl J Med 372, 835- 845 (2015).  
5 Bradley, J., Byington, C. & Shah, S. The management of community -acquired pneumonia in 
infants and children over 3 months of age: clinical practice guidelines by the Pediatric Infectous Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases  
53, e25- e76 (2011).  
6 Haider, B. A., Saeed, M. A. & Bhutta, Z. A. Short -course versus long- course antibiotic therapy for 
non-severe communi ty-acquired pneumonia in children aged 2 months to 59 months. Cochrane 
Database of Systematic Reviews , CD005976 (2008).  
7 Hazir, T., BNisar, Y. & Abbasi, S. Comparison of oral amoxicillin with placebo for the treatment of World Health Organization- defined nonsevere pneumonia in children 2- 59 months: a multi -center, 
double- blind, randomized, placebo- controlled trial in Pakistan. Clinical Infectious Diseases  53, 
293 (2011).  
8 Seppala, H.  et al.  The Effect of changes in the consumption of macrolide antibiotics on 
erythromycin resistance in group A streptococci in Finland. . New England Journal of Medicine 
337, 441- 446 (1997).  
9 Lauber, C., Zhou, N., Gordon, J., Knight, R. & Fierer, N. Effect of storage conditions on the assessment of bacterial community structure in soil and human- associated samples. FEMS 
Microbiology Letters  307, 80 -86 (2010).  
10 Carroll, I., Ringel -Kulka, T., Siddle, J., Lklaenhammer, T. & Y, R. Characterization of the fecal 
microbiota using high- throughput sequencing reveals a stable microbial community during 
storage. PLoS ONE 7, e46953 (2012).  
11 Evans, S. R.  et al.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration 
of Antibiotic Risk (RADAR). Clin Infec t Dis 61, 800- 806 (2015).  
12 Evans, S., Li, L. & Wei, L. Data monitoring in clinical trials using prediction. Drug Inform Journal  
41, 73- 742 (2007).  
13 Li, L., Evans, S., Uno, H. & Wei, L. A graphical tool for data monitoring in clinical trials. Statistical 
Biopharmaceutical Research (2009).  
 
DMID Protocol #14- 0079     Version 4.0  
SCOUT -CAP          14 December 2018  
 ____________________________________________________________________________________________  
62 APPENDIX A – SCHEDULE OF EVALUATIONS 
 
 
 
 
 Initial treatment of 
CAP and 
Eligibility 
Screening1 Enrollment 
Visit Receipt of 
Study Agent2 Outcome 
Assessment 
Visit #1  Outcome 
Assessment 
Visit #2  Early 
Termination 
Visit (as 
applicable)  
Visit Number   1  2 3  
Visit Day Days -5 to 1  Day -3 to -1 Days 1 -5 Day 6 -10 Day 19 -25  
Screening  and Enrollment        
Initially  prescribed antibiotic therapy  X      
Review  of electronic medical records to assess eligibility3 X      
Phone  contact with parent/guardian to assess eligibility  X      
Obtain  Informed Consent   X     
Review  Eligibility Criteria   X     
Medical  History4  X  X X X 
Concomitant  Medications   X  X X X 
Vital Signs (temperature, pulse, respiratory rate)   X  X X X 
Physical Assessment5  X  X X X 
Assess  clinical response to initial antibiotic therapy   X     
Enrollment  and Randomization   X     
Dispense  study agent2  X     
Distribute  Memory Aid and Study -Related Materials   X     
Follow -up       
Receipt  of study agent    X    
Collection  of study product bottle     X X7 X7 
Review  of electronic medical record to assess clinical 
response6    X X X 
Review  Memory Aid     X X X 
Assess  clinical response to therapy     X X X 
Assess  solicited events     X X X 
Collection of Future Use Samples (if consented)        
Throat  Swab   X  X X  
Collection  of stool   X  X X  
DMID Protocol #14- 0079     Version 4.0  
SCOUT -CAP          14 December 2018  
 ____________________________________________________________________________________________  
63  
 
 
Footnotes:  
1. Day -5 is defined as the date on which  the diagnosis  of CAP is made  and treatment  with oral beta- lactam  therapy  is initiated.    
2. Study  drug will be either a continued course  of the oral antibiotic  therapy  that was initially  prescribed (oral amoxicillin,  amoxicillin -clavulanate,  or cefdinir) or a 5 day course of 
matching placebo,  which  will begin  on Day 1. 
3. Electronic  medical  records  will be used to preliminarily  assess eligibility,  including:   age of the subject;  diagnosis  of CAP (a diagnosis  of “pneumonia”  is sufficient)  without  
additional  diagnoses  of bronchiolitis  or croup;  initial antibiotic  therapy  for CAP with sufficient  dose  (i.e., prescription of amoxicillin  or amoxicillin/clavulanate  with an amoxicillin  
dose of 80-100 mg/kg/day  or prescription  of cefdinir of 12-16 mg/kg/d ay); absence  prescription  of any other antibiotic  therapy  ≤7 days  before the diagnosis  of CAP; absence of 
initial  antibiotic  therapy  for CAP with combination therapy  (i.e., amoxicillin,  amoxicillin/clavulanate or cefdinir plus one or more  additional  antibiotics),;  absence of a history  of 
allergy  to amoxicillin  or oral cephalosporin antibiotics  (except  cefaclor);  absence of radiographic  findings  of complicated  pneumonia  (pleural  effusion,  lung abscess,  or 
pneumatocele)  on the initial chest  radiograph (if obtained) or any subsequent  chest  radiograph;  absence of hospi talization for pneumonia during day 1-5 of antibiotic  therapy  for 
CAP;  absence of blood or pleural  fluid culture positive  for S. aureus  or group a streptococcus;  absence  of history  of other conditions  as described  on the exclusion criteria;  any 
other condition that in the judgment  of the investigator  precludes  participation  because it could affect  the safety  of the subject;  current  participation  in any other clinical  trial. 
4. Medical  history  will include acute  or chronic  medical  disorders  of the head,  eyes,  ears,  nose,  throat,  mouth,  cardiovascular  system,  lungs,  gastrointestinal  tract,  liver,  pancreas,  
kidney,  urologic  system,  nervous  system,  blood,  lymph  nodes,  endocrine system,  musculoskeletal  system,  skin, and genital/reproductive  tract.   A history  of any allergies,  cancer,  
immunodeficiency  and autoimmune disease will be solicited.  The history will include capture of sociodemographic data.  
5. A physical  assessment  will be performed to determine general  appearance and hydration status ; vital signs,  including  temperature, pulse,  and respiratory  rate; an assessment  of 
work  of breathing, and presence of skin rash. This can be performed by a nurse, advanced practice nurse, physician assistant, pr physician.  
6. Study  staff will make  a preliminary  EHR- based assessment  of clinical response  to determine  whether any of the following events  occurred  after initiation  of study  drug:   a 
medically  attended  visit to an ED or outpatient  clinic;  receipt  of non-study ant ibiotic  [parenteral  or oral];  treatment  for a local pneumonia complication,  including drainage of pleural  
fluid,  placement  of a chest  tube,  or video assisted thoracoscopic  surgery . 
7. If not collected at previous visi t. 